Reduced Slc1a1 expression is associated with neuroinflammation and impaired sensorimotor gating and cognitive performance in mice: Implications for schizophrenia

Parisa Afshari¹, Wei-Dong Yao¹,², Frank A. Middleton¹,²,³*

¹ Department of Neuroscience & Physiology, SUNY Upstate Medical University, Syracuse, NY United States of America, ² Department of Psychiatry & Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, United States of America, ³ Department of Biochemistry & Molecular Biology, SUNY Upstate Medical University, Syracuse, NY, United States of America

* middletf@upstate.edu

Abstract

We previously reported a 84-Kb hemi-deletion copy number variant at the SLC1A1 gene locus that reduces its expression and appeared causally linked to schizophrenia. In this report, we characterize the in vivo and in vitro consequences of reduced expression of Slc1a1 in mice. Heterozygous (HET) Slc1a1+/− mice, which more closely model the hemi-deletion we found in human subjects, were examined in a series of behavioral, anatomical and biochemical assays. Knockout (KO) mice were also included in the behavioral studies for comparative purposes. Both HET and KO mice exhibited evidence of increased anxiety-like behavior, impaired working memory, decreased exploratory activity and impaired sensorimotor gating, but no changes in overall locomotor activity. The magnitude of changes was approximately equivalent in the HET and KO mice suggesting a dominant effect of the haploinsufficiency. Behavioral changes in the HET mice were accompanied by reduced thickness of the dorsomedial prefrontal cortex. Whole transcriptome RNA-Seq analysis detected expression changes of genes and pathways involved in cytokine signaling and synaptic functions in both brain and blood. Moreover, the brains of Slc1a1+/− mice displayed elevated levels of oxidized glutathione, a trend for increased oxidative DNA damage, and significantly increased levels of cytokines. This latter finding was further supported by SLC1A1 knockdown and overexpression studies in differentiated human neuroblastoma cells, which led to decreased or increased cytokine expression, respectively. Taken together, our results suggest that partial loss of the Slc1a1 gene in mice causes haploinsufficiency associated with behavioral, histological and biochemical changes that reflect an altered redox state and may promote the expression of behavioral features and inflammatory states consistent with those observed in schizophrenia.
Introduction

Excitatory amino acid transporter 3 (EAAT3), known as excitatory amino acid carrier 1 (EAAC1) in rodents, is encoded by the SLC1A1 gene and represents the major neuronal member of the excitatory amino acid transporter family encompassing EAATs 1–5 [1, 2]. EAAT3 is mostly expressed in hippocampus, followed by cerebral cortex, striatum and thalamus. More specifically, the highest transcript levels of EAAT3 in mice are seen in the pyramidal layer of hippocampal areas CA1 to CA4 and the granular layer of the dentate gyrus, where it is widely distributed in all neurons [2, 3, 4].

The EAAT3 protein has three main physiological functions: 1) uptake of synaptic glutamate and preventing the glutamate spillover from active synapses to extrasynaptic regions [1, 5, 6]; 2) providing glutamate as a precursor for gamma aminobutyric acid (GABA) synthesis [1, 7, 8]; and 3) neuronal uptake of cysteine, the rate-limiting substrate for synthesis of intracellular glutathione (GSH) in neurons. In fact, cysteine is transported by EAAT3 at a rate comparable to that of glutamate and with a roughly ten-fold greater affinity than that of the astrocyte transporters, EAAT1 and EAAT2 [9,10, 11,12].

GSH is the principal intracellular antioxidant in neurons, essential for the metabolism of reactive oxygen species (ROS). GSH depletion is associated with increased susceptibility to oxidative stress, which underlies the pathogenesis of neurodegenerative diseases and cognitive impairment [12, 13]. Given that mature neurons rely primarily on EAAT3 for uptake of cysteine and subsequent GSH synthesis [14, 15], it is plausible that this transporter performs essential neuroprotective roles in the brain. Consistent with this idea, EAAT3-null mice present with decreased neuronal GSH levels, increased indicators of neuronal oxidative stress, age-dependent neurodegeneration as well as cognitive impairment and behavioral abnormalities [11, 16, 17]. These mice are also more susceptible to neurodegeneration in models of ischemia, Parkinson’s disease, and aging [8, 11, 18, 19, 20, 21]. Interestingly, it has been observed that treatment of mice with N-acetylcysteine (NAC), a membrane-permeable cysteine precursor, attenuates or prevents the biochemical and behavioral abnormalities in EAAT3-null mice [11, 17, 19, 22].

A tightly regulated balance is known to exist between brain glutamatergic, redox, and inflammatory states, forming what has been termed a “central hub” where imbalances have been hypothesized to contribute to pathophysiological changes associated with schizophrenia and psychosis [23]. Besides confirming the neuroprotective role of EAAT3, some of the studies involving EAAT3-null mice report phenotypes consistent with an effect on GABAergic signaling, which has been strongly linked to some of the core features of schizophrenia [8]. Thus, the function of EAAT3 in glutamate transport, cellular responses to oxidative stress and inflammation, as well as GABA synthesis might form an attractive point of convergence for several pathophysiological models of schizophrenia.

The first group to generate an Slc1a1-knockout mouse strain, in which exon 1 of the gene was disrupted, reported that adolescent mice exhibited decreased spontaneous locomotor activity but did not report any neurodegeneration [24]. However, another group of researchers using descendants of the same knockout strain detected age-dependent behavioral abnormalities and brain atrophy in these mice. These changes were accompanied by reduced neuronal GSH levels and increased histochemical markers of neuronal oxidative stress in the hippocampus [11]. Similarly, Lee and colleagues detected significant deficits in context- and tone-related fear conditioning and Barnes maze performance in adolescent Slc1a1-knockout mice [16]. These reported effects on fear conditioning are highly consistent with parallel studies demonstrating increased translocation of EAAT3 from the cytosol to the plasma membrane in hippocampal CA1 neurons during fear conditioning [25]. Interestingly, many of the reported
neurochemical, neuroanatomical and behavioral alterations could be reversed or prevented by administration of NAC to the knockout mice [11, 17, 19, 20], strongly suggesting that some of the abnormalities are related to the role that this protein plays in cysteine transport and the support of neuronal GSH metabolism, rather than glutamate transport per se [26, 27]. Additional evidence in support of this idea is found in studies of the Gtrp3-18 gene, a negative modulator of EAAT3. Disruption of this gene in mice has been reported to increase the substrate affinity of EAAT3, which in turn elevates neuronal GSH levels and enhances neuronal resistance against oxidative stress [28, 29, 30]. Furthermore, Gtrp3-18-deficient mice have also shown improved performance in spatial/motor learning and memory tasks [31]. Overall, these findings highlight the importance of EAAT3 transporter in normal cognitive and neurochemical brain functions.

Schizophrenia is a disorder with pronounced alteration of cognitive and neurochemical processes, including glutamate, GABA and dopaminergic systems, as well as neuroanatomical changes. For example, reductions in whole brain, medial temporal and prefrontal lobe gray matter volumes have been described in subjects with schizophrenia and have been suggested to correlate with cognitive deficits in the subjects [32, 33, 34, 35]. These abnormalities have also been observed in at-risk individuals or on the first episode, implicating that they are not secondary to the disease or its treatment [36, 37, 38, 39]. There is also accumulating evidence that inflammation and immune dysfunction might contribute to the cognitive, negative, and positive symptoms in schizophrenia [40], with studies reporting abnormal levels of cytokines in both the brain and peripheral blood of patients with schizophrenia. In fact, these data have led to the development of a cytokine-based model of schizophrenia [41], which gains additional support from the characterization of the common genetic liability for schizophrenia associated with the major histocompatibility complex (MHC) and complement Component 4 (C4) genes according to large-scale genome-wide association studies (GWAS) [42].

We previously reported a novel 84-Kb hemi-deletion copy number variant (CNV) in SLC1A1 that exhibits a large effect size causally linked to schizophrenia in a 5-generation family from the Pacific island of Palau [43]. This CNV segregated in an autosomal dominant manner and appeared to act as a loss of function allele, leading to reduced expression of functional SLC1A1 and significantly impairing the ability of cells to transport glutamate and cysteine [44]. Since our report, other groups have also observed similarly localized SLC1A1 CNVs in schizophrenia probands from other populations. Interestingly, these CNVs largely overlap the 5' end of the gene, suggesting that the expression level would be affected in those probands as well [45, 46, 47, 48, 49, 50]. When considered together, the combined genetic data suggest that uncommon CNVs of large effect involving SLC1A1 may help explain a small proportion of the incidence of schizophrenia [44]. However, it is also possible that less severe genetic changes, such as minor allelic variation, could alter the expression of SLC1A1 as well in subjects without CNVs.

While prior studies of SLC1A1 knockout mice have yielded considerable insight into the function of EAAT3 protein, it is clear that the schizophrenic subjects with SLC1A1 hemi-deletions are not well-modeled by complete gene deletions in mice. Therefore, to more closely mimic the effects of the SLC1A1 hemi-deletion on an otherwise normal background, the current study examined the consequences of SLC1A1 haploinsufficiency on brain and behavioral outcomes, using Slc1a1-heterozygous (HET) mice. Notably, the mice used in the present study were obtained from Jackson Laboratory and were generated by disruption of exon 7 of the gene. This construct allowed for inactivation of all potential isoforms of Slc1a1 in mice [51], which prior studies did not accomplish. To our knowledge, there are no published studies on the Slc1a1-HET mice, and none that have attempted to examine behaviors using paradigms that are considered the most relevant for mouse models of schizophrenia, including prepulse
inhibition (PPI) of the acoustic startle reflex, working memory or anxiety-like behavior [52].
Accordingly, the present study examined the above and other behavioral outcomes in Slc1a1-HET mice, with comparisons to KO mice for the behavioral studies included for comparative purposes.

Given the significance of oxidative stress in the pathophysiology of schizophrenia and the important role of EAAT3 in neuronal GSH synthesis, we tested whether Slc1a1 haploinsufficiency could affect the redox state of glutathione (GSH/GSSG ratio) in the brain, as an indicator of cellular oxidative stress. Moreover, since excessive ROS can lead to DNA damage and ultimately cause cell death via apoptosis or necrosis [53], we also assessed the oxidative DNA damage in Slc1a1-HET mice. Oxidative stress can also lead to neuroinflammation and we hypothesized that Slc1a1 haploinsufficiency would increase cytokine production in the brain. This hypothesis was tested using cytokine profiling of mouse brain tissue and human neural cell cultures that were exposed to oxidative stress or pro-inflammatory stimuli after knock-down or over-expression of SLC1A1. Finally, to examine the impact of SLC1A1 haploinsufficiency on global brain function, we used RNA-Seq to determine whether this loss of function produces transcriptional effects on other schizophrenia-related, neuroimmune-related, and synaptic-related genes in the mouse brain tissue. Overall, our results indicate the presence of several behavioral, biochemical, and transcriptional changes in Slc1a1+/− mice that are consistent with its potential utility in modeling schizophrenia and merit further study.

Methods

Slc1a1+/− mice

All procedures were performed with approval of the Committee for Humane Use of Animals (CHUA) at SUNY Upstate Medical University and were in accordance with the guidelines for animal care established by the National Institute of Health. Male and female Slc1a1-HET mice were obtained from The Jackson Laboratory (Stock No. 024411, Bar Harbor, ME) and used as breeding pairs. These animals had been generated from crosses between Slc1a1-knockout (KO) mice on a C57BL/6NJ genetic background and wildtype (WT) mice of the same genetic background. In these knockout mice, exon 7 of the gene had been disrupted by Cre-loxP recombination. Specifically, the exon 7 flanked lox-P construct was introduced into C57BL/6N-derived JM8.N4 embryonic stem (ES) cells, and correctly targeted ES cells injected into B6 (Cg)-Tyrc-2J/J (Stock No. 58) blastocysts. Chimeric male offspring were bred to C57BL/6NJ (Stock No. 005304) females and then to B6N.Cg-Tg(Sox2-cre) 1Amc/J mice (Stock No. 014094) to remove the floxed neomycin and exon 7 sequences. The resulting mice were then bred to C57BL/6NJ mice to remove the Cre-expressing transgene and back-crossed an additional four generations to the C57BL/6N line and maintained as a stock line. Two adult male heterozygous mice (age 13 weeks) and four young adult (age 8 week) non-parous female heterozygous mice were ordered for breeding. Upon arriving at SUNY Upstate Medical University, each male was crossed with two of the females to yield several cohorts for the studies. The first cohort of offspring was not used for analysis. Mice were housed in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Rooms were temperature-controlled (22˚C) and animals were maintained on a 12-h light/dark cycle with ad lib food and water. After crossing, litters were weaned on postnatal day (P) 22–23, ear punches obtained for DNA isolation and identification, and male and female offspring housed in separate cages (of 2–4 mice each). The behavioral, anatomical, and cytokine analyses were performed using the same groups of Slc1a1-HET, WT and KO mice produced during the on-site breeding process. Other biochemical and transcriptional profiling experiments utilized brain tissue from a different set of age-matched, experimentally-naïve WT and HET mice.
Genotyping

Genotypes were determined by polymerase chain reaction (PCR) of ear DNA using the Jackson Laboratory recommended primer pairs. Each mouse was genotyped using two different PCR reactions with either the WT allele-specific primer pair (Forward: 5’ - TACCCCAGTGACTCATCAGC-3’, Reverse: 5’ - CATGGTGTTTACCAGCTGA-3’), or the KO allele-specific primer pair (Forward: 5’ - TTCTACCTCGGGCTAAGA-3’, Reverse: 5’ - CGGTCGCTACCATACACCTAG-3’). Products were separated by 1.5% agarose gel electrophoresis and visualized by ethidium bromide staining. DNA from WT mice produced a single band corresponding to 269 bp, and DNA from KO mice produced a single band at 449 bp, while HET mice DNA produced both bands.

Behavioral tests

A total of 34 mice were used in behavioral experiments (n = 9 HET males, 7 HET females, 5 WT males, 4 WT females, 4 KO males, 5 KO females). Testing was performed in a blind fashion. To minimize the chance of altering the behavioral responses by prior test history, the paradigms were performed in a specific order, which also helped reduce the effects of experimentally-induced anxiety or stress on later outcomes. The order of testing was as follows: Elevated Plus Maze (EPM), performed on P48-49; Y-Maze Spontaneous Alternation (P49-50); Spontaneous Activity in the Open Field (OF) test (P50-52); Novel Object Recognition (NOR) test, performed over two consecutive days (P51-52 and P52-53, respectively); and Pre-pulse Inhibition (PPI) of the Acoustic Startle Response (P53-54). Before each test, the animals were habituated to the behavioral testing room for at least one hour. To remove odor and residues, each apparatus was completely cleaned with 70% ethanol and dried between each test. Also, to reduce the effect of olfactory cues, male animals were always tested before the females.

**Elevated plus maze (EPM) test.** To assess anxiety-like behavior of the animals, the EPM test was conducted using the standard mouse apparatus from San Diego Instruments (San Diego, CA). This apparatus consists of two open and two closed arms, crossing perpendicular to each other at the center. To perform the test, each mouse was placed in the center zone with its head directed toward the open arm and allowed to explore freely. Following an initial 1-minute adaptation period, the number of entries and duration of time spent in each arm as well as the total distance traveled by the animal were recorded for 5 min. A video tracking system utilizing ANY-maze Software (Stoelting, Wood Dale, IL) was used for automated recording and scoring of the behavioral measures. The main contrasts of interests were the total duration of time spent in the open versus closed arms, as well as the total number of entries into the open versus closed arms.

**Y-maze spontaneous alternation test.** The prefrontal cortex has been suggested as the primary site of working memory and subjects with schizophrenia, who are considered to have prefrontal cortical dysfunction, have demonstrated deficits on a variety of working memory tests [54]. To assess spatial working memory, we utilized the Y-maze Spontaneous Alternation test. This test is based on the tendency of rodents to explore new environments. We used a custom-built Y-maze, with plain white fiberboard walls and flooring. The apparatus consisted of three walled arms, 15 inches long and 4.5 inches wide, and positioned at 120° angles from each other with a central triangular zone. Rodents placed in the Y-maze typically prefer to investigate a new arm of the maze rather than returning to one that was previously visited, unless they experience working memory dysfunction or exhibit perseverative behavior. Mice were placed in the center of the maze and allowed to freely explore the three arms for the duration of the test. After an initial 1-minute adaptation time, the total number of entries to the arms, the number of complete alternations (defined by consecutive entry into all three arms on
consecutive choices irrespective of order), total distance traveled, and average speed of each animal were recorded for 5 minutes. ANY-maze software was used for recording and scoring entries and alternations. The fraction of alternation for each animal was calculated as: (number of alternations) / (total number of arm entries – 2). As an additional factor, we also calculated the number of broken alternations, in which after visits to two consecutive arms, re-entry into one of them left the alternation incomplete.

Open field (OF) activity. This test was performed to assess the novel environment exploration, spontaneous locomotor activity and anxiety-related behavior (tendency to avoid the center zone) in the animals. The apparatus was from San Diego Instruments and consisted of a walled-chamber with four square non-transparent open field boxes. The animal was placed in the center of the apparatus under ambient light and allowed to move freely for 10 minutes, following an initial 1-minute adaptation period. Behavioral scoring was accomplished using video tracking with ANY-maze software. A preloaded geometric grid on the computer screen defined the areas of each box as the edge and center zones. The duration of time spent in the center zone, edge zone, total distance traveled and average speed were analyzed as our primary outcome measures. We also examined rotations, entries to the center zone, and the number and duration of freezing/immobile episodes.

Novel object recognition (NOR) test. To evaluate the object recognition memory of the animals, this test was performed over two consecutive days in the OF chamber, for habituation training and object recognition, respectively. One day after completion of the OF test, the mice were placed back into the chamber with the presence of two identical small objects (cubic metal nuts). Using ANY-maze software to divide the OF area accordingly, the number of entries and the duration of time spent in the object interaction zones or background (non-interacting) zones were recorded for 10 minutes, following an initial 1-minute adaptation time. On the second day, the mice were placed back into the same chamber and their behavior recorded for an additional 10 minutes. However, on this day, one of the previous objects was replaced with a novel object (a transparent acrylic cube with a similar size as the cubic metal nuts).

Prepulse inhibition (PPI) of the acoustic startle response. The PPI test is a cross-species measure of sensorimotor gating and its disruption is commonly reported to be an endophenotype of schizophrenia and psychosis [55, 56]. We assessed the potential effects of Slc1a1 haploinsufficiency on PPI performance using commercial startle chambers and the accompanying Startle-Pro software (Med Associates, Fairfax, VT). Each chamber housed a clear non-restrictive container that rested on a platform motion sensor inside a dark, sound-insulated, and ventilated box. All acoustic startle reflex test sessions followed a 10-minute adaptation period during which the animal was left in the dark box without any acoustic stimuli, followed by a 5-minute acclimation period, during which background white noise (62 dB) was present but no other stimuli were presented and no data were collected.

Following this period, the data acquisition was performed over the course of 48 trials separated into three distinct blocks, with pseudorandom inter-trial intervals of 10–20s. Block I: consisted of 10 startle pulses only, where brief (38ms) bursts of sound (120dB) were presented at unpredictable temporal intervals. Block II: consisted of 28 trials of three different types presented in pseudorandom fashion. 4 trials were null, without any pre-pulse or startle stimuli; 4 trials were pre-pulse-only stimuli of 67–76 dB/18ms; 4 trials were startle-only stimuli of 120 dB/38ms, and the remaining 16 trials consisted of startle stimuli (120 dB/38ms), preceded by pre-pulses (67-76dB/18ms). As in Block I, all stimuli were delivered at unpredictable pseudorandom temporal intervals. Block III: consisted of the same stimuli presentations as Block I.

The PPI of startle reflex was calculated as the ratio of average peak values of startle reflexes when the startle stimuli were preceded by prepulses to the average peak values of startle
reflexes when startle stimuli were presented alone, all during block II trials. This ratio was expressed as a percentage change in the ratio.

**Statistical analysis.** Behavioral data were analyzed for significance with NCSS (v11.09; Kaysville, Utah, USA). A General Linear Mixed Model Analysis of Variance (GLMM ANOVA) was used with Genotype and Sex as fixed effects and litter Cohort as a random effect. We focused on detection of significant effects of Genotype, Sex, and Genotype x Sex interactions, with a Dunnett’s post-test used for planned comparisons of both HET and KO groups to the WT group. Results were visualized in tabular form (Table 1) as well as in histograms for the specific behavioral tests that showed a significant difference or a trend for difference between Slc1a1-HET, KO and WT mice (Fig 1). We defined a trend as a change in the KO mice that was in the same direction as a significant change in the HET group that also fell outside the 95th percentile confidence limit (CL) of the mean WT value. Since there were no significant Sex x Genotype interaction effects and no main effect of Sex, histograms for the behavioral studies only separate the data according to Genotype.

**Table 1. Significant behavioral findings and trends in Slc1a1+/- and Slc1a1-/- vs. WT mice.**

| Fraction of Alternation in Y-Maze | DF | Mean Square | F-Value | P-Value | Power | Dunnett’s post-hoc test |
|----------------------------------|----|-------------|---------|---------|-------|------------------------|
| Sex                              | 1  | 4.26E-06    | 0       | 0.9674  | 0.0502|                        |
| Genotype                         | 2  | 0.0167      | 6.67    | 0.0048  | 0.8774| Comparison             |
| Sex * Genotype                   | 2  | 5.06E-05    | 0.02    | 0.9800  | 0.0527| HET                    |
| Cohort                           | 3  | 0.0058      | 2.33    | 0.0989  |        | WT                     |

| Number of Broken Alternations in Y-Maze | DF | Mean Square | F-Value | P-Value | Power | Dunnett’s post-hoc test |
|----------------------------------------|----|-------------|---------|---------|-------|------------------------|
| Sex                                    | 1  | 0.1103      | 0.03    | 0.6102  | 0.0787|                        |
| Genotype                               | 2  | 15.7397     | 3.58    | 0.0017  | 0.9401| Comparison             |
| Sex * Genotype                         | 2  | 7.5529      | 0.06    | 0.9422  | 0.0580| HET                    |
| Cohort                                 | 3  | 17.4752     | 1.57    | 0.2204  |        | MUT                    |

| Ratio of Time Spent in Center: Edges in OF | DF | Mean Square | F-Value | P-Value | Power | Dunnett’s post-hoc test |
|-------------------------------------------|----|-------------|---------|---------|-------|------------------------|
| Sex                                       | 1  | 0.0009      | 0.027   | 0.9674  | 0.0502|                        |
| Genotype                                  | 2  | 0.0281      | 8.34    | 0.0048  | 0.8774| Comparison             |
| Sex * Genotype                            | 2  | 0.0002      | 1.72    | 0.9800  | 0.0527| HET                    |
| Cohort                                    | 3  | 0.0053      | 3.97    | 0.0989  |        | MUT                    |

| Fraction of Time Spent in Object Zones: Background in NOR | DF | Mean Square | F-Value | P-Value | Power | Dunnett’s post-hoc test |
|----------------------------------------------------------|----|-------------|---------|---------|-------|------------------------|
| Sex                                                      | 1  | 0.1123      | 1.06    | 0.9674  | 0.1682|                        |
| Genotype                                                 | 2  | 0.6176      | 5.85    | 0.0048  | 0.8295| Comparison             |
| Sex * Genotype                                           | 2  | 0.0101      | 0.1     | 0.9800  | 0.0630| HET                    |
| Cohort                                                   | 3  | 0.0385      | 0.36    | 0.0989  |        | MUT                    |

| PPI of Startle Reflex | DF | Mean Square | F-Value | P-Value | Power | Dunnett’s post-hoc test |
|----------------------|----|-------------|---------|---------|-------|------------------------|
| Sex                  | 1  | 0.0319      | 0.9     | 0.3508  | 0.1499|                        |
| Genotype             | 2  | 0.1343      | 3.81    | 0.0360  | 0.6380| Comparison             |
| Sex * Genotype       | 2  | 0.0020      | 0.06    | 0.9462  | 0.0575| HET                    |
| Cohort               | 3  | 0.0015      | 0.04    | 0.9881  |        | MUT                    |

* Trend defined as a change in the same direction as HET that exceeded the 95th CL of the WT mean

https://doi.org/10.1371/journal.pone.0183854.t001
Fig 1. Behavioral tests showing significant differences due to Slc1a1-genotype. Behavioral data were analyzed for significance using a General Linear Mixed Model ANOVA incorporating two fixed factors (Genotype, Sex) and one random factor (litter Cohort) followed by a Dunnett’s post-test. There was no significant difference (nsd) in Elevated Plus Maze (EPM) performance, Total Distance Traveled in the Open Field (OF), Novel Object Recognition (NOR) performance, or Acoustic Startle Habituation (panels A, C, G, I), but 5 behaviors including Time Spent in the Center vs Edge of the OF, Y-Maze performance, Prepulse Inhibition (PPI), and overall object interaction time in the NOR (panels B, D, E, F, H) showed significant differences between the HET and WT mice (* = p < 0.05) and were also significantly changed or trending toward a similar change in comparisons of KO and WT mice. A trend was defined as a change in the same direction as the HET mice that exceeded the 95th CL of the WT mean. Since there were no significant Sex x Genotype interaction effects and no main effect of Sex, histograms only indicate Genotype. Data are shown as mean ± SEM. WT, wildtype; HET, Slc1a1-heterozygous; MUT, Slc1a1-KO; PPI, prepulse inhibition.

https://doi.org/10.1371/journal.pone.0183854.g001
Brain morphology measurements

Tissue preparation and histology. The brain tissues from selected mice tested in behavioral phenotyping were used for morphometric measurements (n = 4 HET males, 4 HET females, 2 WT males, 3 WT females). At age P55-75, animals were sacrificed by CO₂ asphyxiation and weighed before decapitation. Brains were then rapidly removed, weighed, snap-frozen in dry ice and stored at −80°C. We first compared the fresh frozen brain wet weight (g) and calculated brain to body weight ratios in HET and WT mice. These data were analyzed using a GLMM ANOVA incorporating Genotype and Gender as fixed effects and litter Cohort as a random effect followed by a Scheffé post-hoc test. To facilitate regional comparisons, the frozen left hemispheres were sectioned in the sagittal plane (30 μm) on a cryostat (Leica Microsystems, Buffalo Grove, IL) and mounted on SuperFrost Plus slides, with each slide containing up to 5 sections. Slides were stored at −80°C until used. For Nissl staining, sections were rapidly thawed, fixed in 4% paraformaldehyde in PBS, stained in 0.5% cresyl violet (wt/vol), dehydrated by submersion in graded ethanols (70, 90 and 100% x 2; vol/vol), placed in xylene and coverslipped using VectaMount mounting medium (Vector Laboratories, Burlingame, CA).

Morphometric measurements. Two sagittal brain sections were selected by two independent raters from all available sections to contain matching levels of the rostral dorsomedial and ventromedial prefrontal cortex (DMPFC and VMPFC) regions, and four sections were chosen from all available sections to contain the matching regions of the dorsal hippocampus. Representative images were then taken from each of the chosen sections blind to mouse genotype using a 4X objective on a Leica AS LMD microscope. NIH ImageJ software was used for measurements in a blind fashion. To test for significant differences in the regional morphometric measures while controlling for repeated sampling of the same mouse and a more robust control of the Type I error rate, we used a two-way (Sex x Genotype) repeated measures ANOVA combining all available measurements for each of the layers as well as the total cortical thickness, followed by a Scheffé post-hoc test, with alpha = 0.05.

Prefrontal cortex. The total cortical thickness of layers II–VI, as well as the widths of individual cortical layers II/III, IV, V, and VI were measured by a blinded rater in duplicate on two different sections for each animal, in both the DMPFC and VMPFC areas.

Hippocampus. Multiple measurements of hippocampal regional morphometry were also performed in a blind fashion, and included the total area of the hippocampal formation, the subareas of the hippocampus proper and dentate gyrus (DG), and the ratio of the hippocampus proper area to the DG area. We also measured the length of the stratum pyramidale (pyramidal cell layer) of the entire cornu ammonis (CA), the length of the stratum granulosum (granule cell layer) in the DG, the total length of these combined, and the ratio of CA to DG lengths. These measurements were obtained on 4 matching section levels through the hippocampus of each animal. Similar to the frontal cortex analysis, to test for significant differences in area or length, we used a two-way (Sex x Genotype) repeated measures ANOVA combining all available measurements.

RNA sequencing

Whole transcriptome profiling was performed on blood and brain tissues of 5 male HET and 5 male WT mice (P48-52), using a stranded RNA-Sequencing (RNA-Seq) approach in the SUNY Molecular Analysis Core (SUNYMAC) facility at Upstate Medical University. Both the blood and brain tissues were supplied by Jackson Laboratories and arrived on dry ice and were immediately stored at -80°C until use. For the blood, RNA was isolated using Qiazol reagent followed by clean up with the RNaseasy Mini Kit (Qiagen, Germantown, MD). For brain tissue RNA purification, the brains were ground into a fine powder in liquid nitrogen using a mortar
and pestle, which was placed on dry ice. The powder was split into three equal aliquots for molecular studies. For RNA sequencing, the total RNA from one aliquot was purified using RNeasy Kit (Qiagen). All RNA samples were subjected to quantification and integrity assessment using the Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA). All of the samples had RIN numbers of at least 9.8 (average 9.98). Libraries were generated using 1.5 ug RNA from each sample according to the TruSeq Stranded Total RNA with Ribo-Zero Globin Kit (Illumina, San Diego, CA). The samples were sequenced using an Illumina NextSeq 500 instrument with 1 x 75 bp single end reads, and a targeted average depth of coverage > 20 million reads per sample. After obtaining the raw sequence reads, FASTQ files were uploaded into BaseSpace (Illumina; https://basespace.illumina.com/apps) for quality control, alignment and quantification of reads to the mm10 build of the mouse genome using the STAR aligner, and differential expression analysis using DE-Seq2 analysis tools within the RNA Express v1.0 application. Raw FASTQ RNA-Seq files for this study are available in the NCBI Gene Expression Omnibus (Accession number: GSE103194). Differences in expression between the HET and WT mice were considered significant after adjusting for multiple testing based on a q value < 0.05. To determine the functional relevance of the most robustly changed genes, we first filtered the genes based on q < 0.01 and an absolute difference exceeding +/- 25% (i.e., log2 change > +/- 0.322) for the brain, or +/- 2-fold for the blood (i.e., log2 change > +/- 1.0) and uploaded the gene lists to the STRING Consortium Database (version 10; http://string-db.org) for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional pathway enrichment analysis and Ingenuity Pathway Analysis (IPA) software (Qiagen) for upstream regulator analysis. Upstream regulator analysis identifies whether common transcriptional modifiers could explain the observed effects on multiple sets of genes. Predictions from the known relationship of the modifier to the outcome are made and examined to determine their overall consistency with the observed effects. In this report, we selected the 20 most robustly predicted upstream regulators for each tissue.

Measurement of glutathione levels

A second aliquot of finely ground powder from the whole brain tissues used for RNA sequencing was used for measurement of glutathione in a total of 10 male mice (n = 5 HET, 5 WT, P48-52, naïve to behavioral testing). The levels of total and oxidized (GSSG) glutathione were measured using the colorimetric Glutathione (GSSG/GSH) Detection Kit (ADI-900-160, Enzo Life Sciences, Farmingdale, NY), according to manufacturer instructions. Briefly, the ground brain tissues were homogenized in ice-cold 5% (wt/vol) metaphosphoric acid (20 mL/g tissue). To measure the oxidized glutathione levels, the samples were treated with 2M 2-vinylpyridine (2 uL per 100 uL of sample homogenate) and incubated at room temperature for 60 minutes prior to being processed. The total and oxidized glutathione samples were diluted 40x and 5x, respectively and read in duplicates. The absorbance was read on a Synergy 2 plate reader (BioTek, Winooski, VT) at 405 nm every minute for a total duration of 11 minutes. The concentrations were calculated based on the slope of absorbance change over the 11 reads obtained at 1-minute intervals after interpolation of the absorbance slope curve of the standard samples provided with the kit. The reduced glutathione (GSH) concentration was calculated by subtracting oxidized glutathione from the total glutathione concentration. Statistical comparisons were made between the reduced to oxidized glutathione ratios (GSH/GSSG) in Scl1a1-HET and WT samples using an unpaired Student’s t-test.

Detection of oxidative DNA damage marker

To determine whether Scl1a1 haploinsufficiency induces oxidative DNA damage, the level of 8-hydroxy-2'-deoxyguanosine (8-OHdG), a sensitive index of such damage in the brain, was
measured. For this purpose, DNA samples from the same homogenized brain tissues mentioned earlier (from 5 HET male and 5 WT male mice) were extracted using the DNeasy Blood & Tissue Kit (Qiagen). Subsequently, 300 ng of each DNA sample was tested in the colorimetric EpiQuik 8-OHdG DNA Damage Quantification Direct Kit (P-6003-48, Epigentek, Farmingdale, NY), following manufacturer instructions. The absorbance was measured on a Synergy 2 plate reader (BioTek) at 450 nm. The results were expressed as absolute quantification (pg) according to the recommended formula and using the standard samples provided with the kit. The calculated 8-OHdG levels were averaged in each genotype group and comparisons were made using an unpaired Student’s t-test.

Apoptosis screening
We used a commercial Luminex-based magnetic bead assay (MILLIPLEX MAP Active Caspase 3 and MILLIPLEX MAP Phospho BAD, Millipore, Billerica, MA) to determine the levels of active caspase-3 and phospho-BAD in the brains of a subset of the same Slc1a1-HET and WT mice used for behavioral phenotyping and morphometry (n = 4 males and 4 females per genotype, n = 16 total). For these assays, samples of the DMPFC and frontal cortex were dissected at -20°C with a 22G needle and homogenized in 300 µL of ice cold Lysis Buffer from the MILLIPLEX MAP Cell Signaling Buffer and Detection Kit (Millipore) with 1% protease inhibitor added. These lysates were diluted 1:1 with 300 µL of Assay Buffer 2 from the same kit, and ultrafiltered with a sterile low protein-binding 0.2 micron syringe filter (Pall, Port Washington, NY). 25 µL of each filtered lysate was used for quantification of caspase-3 and phospho-BAD per manufacturer instructions, using highly specific antibody-coupled magnetic beads (Caspase 3: 46-604MAG, Phospho-BAD: 46-694MAG, Millipore). To control for total protein amounts, we included a third antibody-coupled magnetic bead to quantify beta-tubulin (46-713MAG, Millipore). After the primary antibody incubations, samples were washed, incubated with detection antibody, washed again, and then each well was filled with 150 µL Assay Buffer. Plates were read with a Bio-Plex 200 instrument (Bio-Rad, Hercules, CA). The median fluorescent intensity (MFI) was measured for at least 100 beads per target protein in each well, and the background intensity was subtracted using a control well. Ratios of the active caspase-3 to beta-tubulin and phospho-BAD to beta-tubulin were then compared between the mice in different groups. Comparisons between the groups were performed using a 2-way ANOVA (Sex x Genotype), with a Scheffe post-hoc test used to control for possible non-normality of the ratio data.

Cytokine profiling
We also sought to examine the possible evidence for an increased inflammatory state in the brains of the Slc1a1-HET mice. This was performed using the same brain lysate samples prepared for the apoptosis assays. For the profiling, we used the MILLIPLEX MAP Cytokine/Chemokine Magnetic Bead Panel (RECYMAG65K27PMX, Millipore) to simultaneously screen for changes in 27 cytokines using highly specific antibody-coupled magnetic beads. The cytokines included in this assay were EGF, Eotaxin/CCL11, Fractalkine, G-CSF, GM-CSF, GRO/KC, IFNgamma, IL-1alpha, IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, IL-17A, IL-18, IP-10, Leptin, LIX, MCP-1, MIP-1alpha, MIP-2, TNF-alpha, RANTES and VEGF. Plates were prepared per manufacturer instructions using 25 µL of each lysate per well. Briefly, each well of the 96-well assay plate was blocked with wash buffer for 10 minutes before use. The assay standards included with the kit were prepared by 4-fold serial dilutions. After adding the experimental or standard samples to the appropriate wells and serum matrix to the background wells, the antibody-immobilized beads were dispensed into each well and incubated...
with agitation overnight at 4°C. The next day, the wells were washed and incubated with a detection antibody, followed by streptavidin, additional washing, and resuspension in sheath fluid for reading on the Bio-Plex 200 plate reader. To calculate the cytokine concentrations (pg/mL) in the samples and controls, the MFI was analyzed using a 5-parameter logistic method after background correction. To control for different amounts of total protein in the lysates, the cytokine values were normalized to the levels of β-tubulin previously determined for each lysate. Comparisons between the groups were performed using a 2-way ANOVA (Sex x Genotype), with a Scheffe post-hoc test to control for possible non-normality.

**Effects of knockdown or over-expression of SLC1A1 on neural cytokine production**

Based on the results from the cytokine profiling in Slc1a1-HET and WT mice, we next evaluated how the expression level of SLC1A1 transcript might affect the response of differentiated human neuroblastoma SK-N-SH cells to oxidative stress or pro-inflammatory stimuli.

**Cell culture.** Aliquots of the human SK-N-SH cell line were obtained from Dr. Yanli Zhang-James (SUNY Upstate). Cells were cultured in D-MEM medium (Thermo Fisher Scientific, Waltham, MA), supplemented with 10% fetal bovine serum (FBS) and 100 U/mL Penicillin-Streptomycin (Thermo Fisher Scientific) and incubated in humidified atmosphere at 37°C with 5% CO₂. For differentiation, cells were plated into 0.1% gelatin-coated dishes at a density of 10 x 10^3 cells per cm² and grown as a monolayer in DMEM+. One day after plating, 10 μM retinoic acid (Sigma-Aldrich, St. Louis, MO) dissolved in dimethyl sulfoxide (DMSO) was added to the culture medium. The medium was replaced on alternate days and the cells were allowed to differentiate for 2 weeks to adopt a neural-like phenotype.

**Transfection of SLC1A1 shRNA or cDNA.** All transfections were performed using the Nucleofection platform with the 4-D Nucleofector System (Lonza, Walkersville, MD) and Cell Line Nucleofector Kit V (VCA-1003, Lonza). For the knockdown studies, a cocktail of three validated human MISSION SLC1A1 shRNAs (SHCLNG-NM_004170, Sigma-Aldrich) or pLKO1-puro non-target shRNA (Sigma-Aldrich) as a negative control were used. For the overexpression studies, GFP-tagged full-length SLC1A1 construct was used. The construct contained the sequence-verified WT human SLC1A1 ORF (1575 bp) subcloned into pCMV6-AC-GFP vector (PS100040, Origene, Rockville, MD). According to manufacturer instructions, PmaxGFP plasmid was used as the positive control for measuring the nucleofection efficiency. On the day of transfection, differentiated SK-N-SH cells were harvested by trypsinization and counted. For each transfection condition, 1 x 10^5 cells were centrifuged in an individual Eppendorf tube at 90g for 10 min and the Nucleofector Solution was added. After adding either 0.2 ug of cDNA construct or 20 nM of SLC1A1- or non-target shRNA to each tube, the nucleofection procedure was performed and nucleofected cells were plated in a 96-well plate using eight replicate wells for each transfection condition (i.e., a total of 32 wells). Cells were maintained for 48 hours before checking the fluorescence intensity with a microscope to estimate transfection efficiency. For these studies, the transfection efficiency was estimated at 80% (data not shown).

**Quantitative confirmation of overexpression and knockdown of SLC1A1.** 48 hours after nucleofection, the RNA from two wells in each transfection condition was isolated using the RNeasy Mini Kit (Qiagen) and 500 ng of RNA was used to synthesize cDNA using the Quantitect Reverse Transcription Kit (Qiagen). To quantitatively confirm the SLC1A1 overexpression or knockdown in nucleofected human SK-N-SH cells, real-time RT-qPCR was performed in triplicate reactions with a custom-designed primer pair that amplified a 102-bp sequence in exon 10 of the gene (left primer: 5’-ATTCGTGTTACCCGTTGGTG-3’; right primer: 5’-CCCAAGTCCAGGTCCATTCAA-3’). Thermal cycling was performed using 5 uL of
cDNA from each sample, with 0.5 μL of each forward and reverse primers in a standard qPCR reaction in 20 μL volumes using LightCycler 480 SybGreen I Master Mix (Roche, Indianapolis, IN) and the following conditions: 95°C for 5 min, then 40 cycles of 95°C for 15 sec, 39°C for 10 sec and 72°C for 15 sec. Quantification was performed using the delta delta Ct method, with human RPLP1 used as the reference gene. Resulting data were log2 scaled and comparisons were made between the control, cDNA, and shRNA samples using a Welch’s t-test.

**Treatment of cells with oxidative stress or proinflammatory stimuli.** In each set of transfected cultures, SK-N-SH cells were treated with either: 1) lipopolysaccharide (LPS, Sigma-Aldrich) at a concentration of 100 ng/mL, or 2) rotenone (Sigma-Aldrich) dissolved in 0.01% DMSO at a concentration of 100 nM, or 3) 0.01% DMSO as the vehicle. Each experimental condition was performed in duplicate wells and maintained for 48 hours.

**Cytokine profiling.** The supernatant in each well was collected and centrifuged. Using the Human High Sensitivity T-Cell Magnetic Bead Panel (HSTCMAG28SPMX21, Millipore), the levels of 21 different cytokines were quantified in each supernatant. The cytokines included in this assay were Fractalkine, GM-CSF, IFNgamma, IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, IL-21, IL-23, ITAC, MIP-1alpha, MIP-1beta, MIP-3alpha and TNFalpha. Plates were prepared and analyzed as described earlier. The MFI values were adjusted for the background and the replicates averaged across the two plasmid control conditions (scrambled shRNA and PmaxGFP) for display purposes. Statistical comparisons were made using a 2-way ANOVA incorporating 3 different treatments (DMSO, rotenone or LPS) and 3 different plasmids (control, cDNA, shRNA). Hierarchical clustering was then performed to help visualize changes in cytokine levels across the conditions, and histogram plots made for selected proteins.

**Results**

**Behavioral outcomes**

**Reduced Slc1a1 increases anxiety-like behavior.** Since anxiety is a highly prevalent comorbidity of schizophrenia [55], we investigated whether Slc1a1-HET mice would exhibit more anxiety-like behavior, compared to WT mice. Our results with the Elevated Plus Maze (EPM) showed a non-significant increase in time spent in the closed versus open arms of the maze, but this difference did not achieve significance (Fig 1; Table 1). However, we did observe significantly reduced Center: Edge time in the Open Field (OF) task in both HET and KO (MUT) mice along with no difference in Total Distance Traveled in the OF. In addition, we found no significant effects of Sex, or Sex x Genotype interactions, in either of these measures. Notably, the magnitude of the effect was equivalent in the KO and KO mice. Together, these observations are consistent with a likely increase in anxiety-like behavior as a result of reduced Slc1a1 expression.

**Reduced Slc1a1 impairs working memory.** Impairment of working memory, including its spatial domain, is considered one of the core cognitive impairments in schizophrenia [56]. Working memory is often used to monitor prior choices in order to guide future actions. We attempted to assess the working memory of Slc1a1-HET and KO mice using the Y-maze spontaneous alternation test. Slc1a1-HET and KO mice showed significantly and equivalently reduced fractions of alternations compared to WT mice (Fig 1; Table 1) along with equivalently increased broken alternations compared to WT mice (Fig 1; Table 1) and no significant effects of Sex or Sex x Genotype interactions. Our results suggest that working memory is disrupted in mice with reduced expression of the Slc1a1 gene.

**Reduced Slc1a1 does not influence locomotor activity of mice.** Locomotor hyperactivity is sometimes reported in mouse models of schizophrenia and psychosis [57, 58]. Thus, we
examined the locomotor activity of Scl1a1-HET and WT mice as measured by the total distance traveled in the OF test and the other tests. As already noted, our data revealed no significant effect of Genotype or Sex on the total distance traveled in the OF test (Fig 1) or in the EPM, NOR, and Y-Maze tests (not shown). The lack of any effect on overall locomotor activity is consistent with previous data on the Scl1a1 KO mice.

**Reduced Scl1a1 decreased exploration of objects.** In the Novel Object Recognition (NOR) test, the ratio of exploration time for the novel object vs. familiar object was not significantly different in Scl1a1-HET and WT mice, and there was no preference for the novel object over the familiar object in either of the genotypes (Fig 1). This lack of preference could not be attributed to the position of the objects inside the boxes, as the ratio of time spent in the object zones was similar in habituation and recognition test days in both genotypes (data not shown). However, we did observe a significant main effect of Genotype on exploratory activity toward the object zones in general (Fig 1, Table 1), as measured by total duration of time spent in either object zone compared to background, which was significantly reduced in HET mice and showed the same trend in KO mice. For simplicity, the exploratory activity data from habituation and test days were combined and displayed in a single histogram. These observations suggest that there is a reduction of general interest or attention for the objects in Scl1a1-HET mice, compared to the WT mice.

**Reduced Scl1a1 impairs prepulse inhibition.** As a measure of sensorimotor gating, the disruption of prepulse inhibition (PPI) of the acoustic startle reflex is commonly accepted as an endophenotype of schizophrenia [57, 59]. We detected a significant effect of Genotype on PPI ($F_{2,33} = 3.81$, $p = 0.036$) with a trend for decreased PPI in both HET and KO mice (post-hoc $p = 0.0243$ and 0.1548 respectively) (Fig 1; Table 1). No significant effects of Sex or Sex x Genotype interaction were observed. These results suggest that Scl1a1-HET mice exhibit a deficit in sensorimotor gating function, a fundamental form of information processing that appears to be deficient in different models of schizophrenia [60].

**Morphological changes**

**No overall difference in brain mass due to genotype.** Despite a tendency for females to have lower brain weights than males, there was no significant difference in overall fresh frozen brain weight due to Genotype ($F_{1,11} = 0.39$, $p = 0.549$), Sex ($F_{1,11} = 2.88$, $p = 0.128$), or the interaction of Genotype x Sex ($F_{1,11} = 0.01$, $p = 0.931$) (data not shown). However, Brain:Body Weight ratios did show a significant effect of Sex ($F_{1,11} = 12.04$, $p = 0.008$), but no effect of Genotype ($F_{1,11} = 0.41$, $p = 0.541$) or Genotype x Sex interaction ($F_{1,11} = 1.25$, $p = 0.296$) (not shown).

**The thickness of DMPFC is reduced in Scl1a1+/− mice but VMPFC thickness and hippocampal size remain unchanged.** Volumetric reductions of prefrontal cortex have been observed in subjects with schizophrenia, which have correlations with the severity of cognitive and negative symptoms of the disease [61, 62]. There are also inconsistent reports of reduced hippocampal volume in schizophrenia [63]. To examine whether Scl1a1+/− mice show brain morphological changes including reduced cortical thickness in prefrontal cortex and reduced size of the hippocampus, we performed morphometric analysis of Nissl-stained sagittal brain sections.

**Prefrontal cortex.** Overall cortical thickness was significantly reduced ($F_{1,7} = 8.88$, $p = 0.021$) in the DMPFC of Scl1a1-HET mice compared to WT mice, but there were no differences in the VMPFC thickness ($F_{1,4} = 2.76$, $p = 0.172$) between genotypes. We also did not find any significant effects of Sex, Section Level, or Sex x Genotype interactions on overall cortical thickness in either region. The difference in the DMPFC thickness was further supported
by a significant post-hoc result (Scheffé p = 0.009). The results of two-way ANOVAs for each cortical layer in the DMPFC and VMPFC indicated that only layer V of the DMPFC was significantly affected due to Genotype (-21.8% reduction; F\textsubscript{1,8} = 7.49, p = 0.0256) (Fig 2). Other
layers showed trends for decreased thickness in both regions, but none were significantly affected at the \( p < 0.05 \) level.

**Hippocampus.** Although there was a highly significant effect of Section Level on multiple hippocampal morphometry measures, there were no significant main effects of Genotype or Sex. However, we observed two nominally significant interaction effects. The area of the hippocampus proper exhibited a significant Section Level x Genotype interaction (\( F_{(3,30)} = 2.99, p = 0.0467 \)) and the ratio of the Hippocampus Proper/ DG areas showed a significant Section Level x Genotype x Sex interaction (\( F_{(3,30)} = 3.95, p = 0.0173 \)). Inspection of the data revealed that these effects were likely caused by slightly different gradients from medial to lateral regions of the hippocampus in the different animal subgroups (Fig 3). Although the measurements were performed completely blindly by a single rater, and the standard errors were acceptably small, we cannot fully exclude the possibility of sampling artifacts contributing to these findings.

**Transcriptional effects**

**RNA expression changes in Slc1a1+/- mouse brains are related to synaptic and cognitive functions.** To examine the global consequences of *Slc1a1* haploinsufficiency on the expression of other genes, we used a stranded RNA-Seq approach to assess the whole brain and whole blood transcriptomes in *Slc1a1*-HET (n = 5) and WT (n = 5) mice. The average read length was 72 bases with an average quality score of 35. For the brain, an average of 23.3M reads were quantified in each sample, with > 95% alignment to the mm10 mouse genome. Approximately 81% of the aligned reads were classified as exonic, and were located within 23,420 annotated genes. For the whole blood samples, an average of 21.6M reads were obtained per sample, with 83% alignment to the Mm10 genome and 55% classified as exonic. Only genes with a mean count across all samples of 10 or more, and genes whose differential expression result was not determined to be due to a single outlier sample were included in downstream analysis of the brain data (n = 13,542) and blood data (n = 10,160).

Comparisons of gene expression levels between the two genotype groups were made using DE-Seq2 in separate analyses for each tissue type. For the brain, differences in expression were considered significant based on a \( q \) value < 0.01 and an absolute difference exceeding +/- 1.25-fold (i.e., \( \log_2 \) change > +/- 0.322). For the blood, differences were considered significant based on a \( q \) value < 0.01 and an absolute difference of more than +/- 2-fold (i.e., \( \log_2 \) change > +/- 1.0). For the brain tissue comparisons, a total of 45 genes were found to be differentially expressed in the HET vs. WT samples (Table 2). These genes included *Slc1a1* itself (\( q \) value = 0), which was found to decrease 2-fold (\( \log_2 \) change = -1.0), as well as several other genes with known roles in the brain development, neuronal activity, signaling and transport functions. To further probe the functions of these genes, we performed functional enrichment analysis using the STRING Consortium Database after filtering on an absolute difference exceeding +/- 25% (i.e., \( \log_2 \) change > +/- 0.322). This indicated over-representation of: Biological Process ontologies involved in Cognition as well as Learning or Memory; Cellular Component ontologies involved in Postsynaptic Density, Dendritic Spine, and Neuron Projection; and KEGG Pathway ontologies involved in Glutamatergic Synapse and Amphetamine Addiction (Table 3).

**RNA expression changes in Slc1a1+/- mouse blood are related to immune activity and inflammation.** For the whole blood comparisons, a total of 74 genes were found to be differentially expressed. Interestingly, the most significant of these genes included Jun B (\( q = 2.7e-22 \)), Jun (\( q = 1.9e-15 \)), and Fos (\( q = 4.8e-8 \)) (Table 4), which are highly related immediate early genes involved in numerous cellular responses (e.g., stress, inflammation, immune activity). The STRING analysis further probed the functions of all of the differentially expressed blood genes, and indicated over-representation of several Biological Process ontologies involved in...
immune activation, cytokine responses, inflammation, and drug responses, among others (Table 5). Similarly, KEGG Pathway ontologies over-represented in the significantly changed genes included several involved in cytokine signaling, infection, and inflammation (Table 5).
### Table 2. Differentially expressed genes in brain tissue of Slc1a1-HET and WT mice.

| Gene     | Log2 Change | q value | Gene Title                                                                 |
|----------|-------------|---------|----------------------------------------------------------------------------|
| Slc1a1   | -1.02       | 0       | Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 |
| Scube1   | -0.7        | 2.46E-10| Signal peptide, CUB domain, EGF-like 1                                      |
| Arc      | 0.95        | 1.99E-08| Activity regulated cytoskeletal-associated protein                          |
| Dact2    | -0.47       | 0.0001  | Dapper homolog 2, antagonist of beta-catenin (xenopus)                      |
| Lmo7     | -0.55       | 0.0002  | LIM domain only 7                                                           |
| Trb1     | -0.59       | 0.0003  | T-box brain gene 1                                                          |
| Rgs14    | -0.53       | 0.0004  | Regulator of G-protein signaling 14                                          |
| Creld2   | 0.43        | 0.0006  | Cysteine-rich with EGF-like domains 2                                        |
| Junb     | 0.63        | 0.0009  | Jun-B oncogene                                                              |
| G530011O06Rik | -1.07   | 0.0016  | RIKEN cDNA G530011O06 (non-coding RNA gene)                                  |
| Slc17a7  | -0.37       | 0.0016  | Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 |
| Rhpn2    | 0.46        | 0.0017  | Rhophilin, Rho GTPase binding protein 2                                      |
| Tnfaip6  | 0.5         | 0.0018  | Tumor necrosis factor alpha induced protein 6                               |
| Dbp      | -0.47       | 0.0028  | D site albumin promoter binding protein                                      |
| Ormdl2   | 0.43        | 0.0028  | ORM1-like 2 (S. cerevisiae)                                                  |
| Agtli21  | 0.45        | 0.0029  | Alanine-glyoxylate aminotransferase 2-like 1                                |
| Ap1m1    | -0.66       | 0.0029  | Adaptor-related protein complex AP-1, mu subunit 1                          |
| Slitrk5  | -0.53       | 0.003   | SLIT and NTRK-like family, member 5                                          |
| Ccdc28b  | 0.39        | 0.0033  | Coiled coil domain containing 28B                                           |
| Slitrk3  | -0.32       | 0.0035  | SLIT and NTRK-like family, member 3                                          |
| Ppp113c  | 0.34        | 0.0037  | Protein phosphatase 1, regulatory (inhibitor) subunit 3C                    |
| Cntrob   | -0.57       | 0.0039  | Centrobin, centrosomal BRCA2 interacting protein                            |
| Zfp948   | 0.37        | 0.0042  | Zinc finger protein 948                                                      |
| Grn2a    | -0.41       | 0.0057  | Glutamate receptor, ionotropic, NMDA2A (epsilon 1)                          |
| Slc6a6   | -0.53       | 0.0059  | Solute carrier family 6 (neurotransmitter transporter, taurine), member 6   |
| Zfp318   | -0.33       | 0.0059  | Zinc finger protein 318                                                      |
| Slit3    | -0.49       | 0.0062  | Slit homolog 3 (Drosophila)                                                  |
| Gm14420  | 0.34        | 0.0062  | Predicted gene 14420                                                        |
| Nr1d1    | -0.64       | 0.0063  | Nuclear receptor subfamily 1, group D, member 1                              |
| Foxg1    | -0.6        | 0.0063  | Forkhead box G1                                                             |
| Ccsap    | -0.46       | 0.0063  | RIKEN cDNA 1700054N08 gene                                                   |
| Zfp449   | 0.33        | 0.0063  | Zinc finger protein 449                                                      |
| P4ha1    | 0.41        | 0.0065  | Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide |
| Efnb2    | -0.49       | 0.0073  | Ephrin B2                                                                   |
| Sorcs3   | -0.44       | 0.0076  | Sortilin-related VPS10 domain containing receptor 3                         |
| Lama4    | -0.37       | 0.0076  | Laminin, alpha 4                                                            |
| Adipor2  | 0.42        | 0.0076  | Adiponectin receptor 2                                                       |
| Srsf5    | -0.43       | 0.008   | Serine/arginine-rich splicing factor 5                                        |
| Kalm     | -0.37       | 0.008   | Kalirin, RhoGEF kinase                                                       |
| Lingo1   | -0.35       | 0.008   | Leucine rich repeat and Ig domain containing 1                              |
| Tcerg1   | -0.33       | 0.008   | Transcription elongation regulator 1 (CA150)                                  |
| Chrm1    | -0.47       | 0.0084  | Cholinergic receptor, muscarinic 1, CNS                                       |
| Prkca    | -0.4        | 0.0085  | Protein kinase C, alpha                                                      |
| Tmem86a  | -0.41       | 0.0087  | Transmembrane protein 86A                                                    |
| Chpf2    | -0.45       | 0.0089  | Chondroitin polymerizing factor 2                                             |

https://doi.org/10.1371/journal.pone.0183854.t002
Upstream regulator analysis reveals possible common transcriptional regulators of differentially expressed genes in brain and blood. Although the most significantly affected genes differed for brain and blood, we tested whether common upstream regulators might explain part of the overall set of changes that were seen in the two tissue types. Each tissue showed evidence of possible upstream regulators of the most robustly changed genes (Table 6). For blood, most of the top predicted upstream regulators were related to immune and proinflammatory pathways. Unexpectedly, for brain, the top predicted upstream regulators included growth factors, dopamine and several related to cellular activity, but also included several related to inflammation and immune activation that were also seen for the blood (Table 6, bold entries). The predicted effects of these common upstream regulators were visualized to indicate the direction of change and relatedness to each other (Fig 4). This analysis indicated the potential for changes in four common endogenous upstream regulators (APP, IFNG, IL1B, and TNF) to produce several of the observed effects in both tissues, as well as the potential for two exogenous compounds, including lipopolysaccharide (LPS) and phorbol myristate acetate (PMA) to produce similar effects.

Biochemical changes

Glutathione redox imbalance in the brain of Slc1a1−/− mice. A decreased ratio of reduced to oxidized glutathione concentration (GSH/GSSG) is an indicator of cellular toxicity that can occur under oxidatively stressful conditions [64]. Moreover, this type of glutathione redox imbalance has been consistently reported in subjects with psychiatric disorders [65]. Consistent with these findings, we found that the ratio of GSH/GSSG in the brains of Slc1a1-HET mice is almost half of what detected in WT mice (p = 0.012) (Fig 5), implicating a potential redox imbalance and higher vulnerability to oxidative stress in response to Slc1a1 haploinsufficiency.

Increased levels of oxidative DNA damage marker in Slc1a1−/− mice. Based on the glutathione results, we next sought to examine whether Slc1a1 deficiency might cause oxidative DNA damage in the brain. The data from the 8-OHdG quantification kit indicated a trend for 2.7-fold higher concentration of this oxidative DNA damage marker in the brains of Slc1a1−/− mice.
Table 4. Differentially expressed genes in blood tissue of **Slc1a1**-HET and WT mice.

| Gene       | Log2 Change | q Value   | Gene Title                                                                 |
|------------|-------------|-----------|-----------------------------------------------------------------------------|
| Junb       | 1.43        | 2.70E-22  | Jun-B oncogene                                                             |
| Jun        | 1.51        | 1.90E-15  | Jun oncogene                                                                |
| Sowaha     | 1.17        | 2.70E-08  | Sosondowah ankyrin repeat domain family member A                           |
| Fos        | 1.46        | 4.80E-08  | FBJ osteosarcoma oncogene                                                  |
| Apol11a    | 1.68        | 9.10E-08  | Apolipoprotein L 11a                                                       |
| Cirbp      | -1.03       | 1.40E-07  | Cold inducible RNA binding protein                                          |
| 1810053B23Rik | 1.95    | 1.40E-07  | RIKEN cDNA 1810053B23 gene                                                  |
| Rgs1       | 1.6         | 1.90E-07  | Regulator of G-protein signaling 1                                         |
| Lars2      | 1.42        | 1.70E-06  | Leucyl-tRNA synthetase, mitochondrial                                       |
| Ccl3       | 1.58        | 1.70E-06  | Chemokine (C-C motif) ligand 3                                              |
| Osm        | 1.47        | 1.90E-06  | Oncostatin M                                                                |
| Gfap       | 1.15        | 2.80E-06  | Gial fibrillary acidic protein                                              |
| Ccl4       | 1.45        | 9.20E-06  | Chemokine (C-C motif) ligand 4                                              |
| Plk3       | 1.3         | 2.70E-05  | Polo-like kinase 3                                                          |
| Tbx21      | 1.18        | 3.30E-05  | T-box 21                                                                    |
| Slc16a1    | 1.04        | 0.0001    | Solute carrier family 16 (monocarboxylic acid transporters), member 1       |
| Fads1      | 1.04        | 0.0001    | Fatty acid desaturase 1                                                     |
| Dtl        | 1.17        | 0.0002    | Denticleless homolog (Drosophila)                                           |
| Cespi      | 1.13        | 0.0002    | Centromere protein 1                                                        |
| Gm10785    | 1.15        | 0.0002    | Predicted gene 10785 (Mus musculus)                                         |
| Sgo1       | 1.01        | 0.0003    | Shugoshin-like 1 (S. pombe)                                                 |
| Ermap      | 1.02        | 0.0003    | Erythroblast membrane-associated protein                                    |
| Tjp1       | 1.16        | 0.0003    | Tight junction protein 1                                                    |
| Gm166      | 1.11        | 0.0003    | Predicted gene 166                                                          |
| Vangl1     | 1.08        | 0.0004    | Vang-like 1 (van gogh, Drosophila)                                          |
| Tnfrsf9    | 1.2         | 0.0004    | Tumor necrosis factor receptor superfamily, member 9                        |
| Ppp1r15a   | 1.01        | 0.0004    | Protein phosphatase 1, regulatory (inhibitor) subunit 15A                   |
| Irf7       | 1.01        | 0.0004    | Interferon regulatory factor 7                                               |
| Wipi1      | 1.14        | 0.0005    | WD repeat domain, phosphoinositide interacting 1                           |
| Rhd        | 1.07        | 0.0005    | Rh blood group, D antigen                                                   |
| Syt14      | 1.05        | 0.0006    | Synaptotagmin XIV                                                           |
| Sh3d19     | 1.07        | 0.0006    | SH3 domain protein D19                                                      |
| Dusp1      | 1.1         | 0.0006    | Dual specificity phosphatase 1                                              |
| Snord110   | -1.25       | 0.0006    | Small nucleolar RNA, C/D box 110                                            |
| Cdc6       | 1.01        | 0.0006    | Cell division cycle 6                                                       |
| Ppap2a     | 1.12        | 0.0006    | Phosphatidic acid phosphatase type 2A                                        |
| Slit1      | 1.2         | 0.0006    | Slit homolog 1 (Drosophila)                                                 |
| Redrum     | 1.2         | 0.0007    | Redrum, erythroid developmental long intergenic non-protein coding transcript|
| Mpc2       | 1.06        | 0.0007    | Mitochondrial pyruvate carrier 2                                            |
| Fbxo30     | 1.02        | 0.0008    | F-box protein 30                                                            |
| Darc       | 1.12        | 0.0009    | Duffy blood group, chemokine receptor                                        |
| Crat       | 1.03        | 0.001     | Carnitine acetyltransferase                                                  |
| Kit        | 1.08        | 0.0011    | Kit oncogene                                                                |
| Scn4a      | -1.24       | 0.0011    | Sodium channel, voltage-gated, type IV, alpha                              |
| Oas1e      | 1.31        | 0.0013    | 2'-5' oligoadenylate synthetase 1E                                          |
| Tmod1      | 1.05        | 0.0013    | Tropomodulin 1                                                              |
| Fcer2a     | -1.05       | 0.0014    | Fc receptor, IgE, low affinity II, alpha polypeptide                        |

(Continued)
HET mice compared to WT mice (Fig 6). However, the difference was not significant. Although the results are merely suggestive, they might indicate increased vulnerability of Slc1a1-HET mouse brain cells for DNA damage as a consequence of impaired cellular oxidant metabolism.

**Slc1a1 haploinsufficiency does not alter brain apoptosis.** Although the exact role of apoptosis in schizophrenia remains uncertain, there have been reports of dysregulation of apoptosis and possible increase in apoptotic susceptibility in several brain regions of individuals with schizophrenia [66]. On the contrary, accumulating evidence suggests that apoptotic activity may be downregulated in chronic schizophrenia [67, 68], although this effect may be influenced by administration of anti-psychotic medications (which can have anti-inflammatory effects). On the other hand, EAAT3 has been suggested to have direct anti-apoptotic activity in neurons [69]. Thus, to address possible changes in apoptosis in Slc1a1-HET and WT mice, we measured the levels of active caspase-3 and phospho-BAD in the brains of a subset of the same mice used in behavioral phenotyping and morphometric experiments. Our data did not indicate any significant differences in the levels of caspase-3 or phospho-BAD between the two genotype groups (Slc1a1-HET and WT). However, we detected a non-significant trend for increased levels of active caspase-3 in male Slc1a1+/− mice, compared to male WT mice (data not shown). The analysis also did not reveal any significant effects of Sex or Sex x Genotype interaction on the levels of either apoptosis marker. Since the calculated concentrations of active caspase-3 and phospho-BAD were normalized to the levels of beta-tubulin, the findings cannot be attributed to different amounts of total protein in the lysates.

**Increased production of cytokines in Slc1a1+/− mice.** Cytokines are one of the most important components of the immune system that mediate the response to infectious and

### Table 4. (Continued)

| Gene          | Log2 Change | q Value | Gene Title                          |
|---------------|-------------|---------|-------------------------------------|
| Prnp          | 1.08        | 0.0016  | Prion protein                       |
| 5830428M24Rik | -1.03       | 0.0017  | RIKEN cDNA 5830428M24 gene          |
| Rrm2          | 1.01        | 0.0017  | Ribonucleotide reductase M2         |
| Ctsf          | 1.02        | 0.0018  | Cathepsin F                         |
| Clnk          | 1.08        | 0.0018  | Cytokine-dependent hematopoietic cell linker |
| Tnk1          | 1.1         | 0.002   | Tyrosine kinase, non-receptor, 1    |
| Mylpf         | 1.07        | 0.0021  | Myosin light chain, phosphorylatable, fast skeletal muscle |
| Klr2          | 1.05        | 0.0021  | Killer cell lectin-like receptor family I member 2 |
| Hist1h2bp     | 1.12        | 0.0024  | Histone cluster 1, H2bp             |
| Erdr1         | -1.13       | 0.0026  | Erythroid differentiation regulator 1 |
| Gypa          | 1.02        | 0.0026  | Glycoporphin A                      |
| Cyp4b1-ps2    | 1.07        | 0.0029  | Cytochrome P450, family 4, subfamily b, polypeptide 1, pseudogene 2 |
| Ifng          | 1.23        | 0.003   | Interferon gamma                    |
| Fasl          | 1.03        | 0.0038  | Fas ligand (TNF superfamily, member 6) |
| BC020402      | -1.02       | 0.0043  | cDNA sequence BC020402              |
| Crisp2        | 1.03        | 0.0044  | Cysteine-rich secretory protein 2   |
| Socs2         | 1.07        | 0.0047  | Suppressor of cytokine signaling 2  |
| Jpx           | -1.06       | 0.005   | Jpx transcript, Xist activator (non-protein coding) |
| Ska1          | 1.07        | 0.0051  | Spindle and kinetochore associated complex subunit 1 |
| Cib3          | 1.01        | 0.0064  | Calcium and integrin binding family member 3 |
| Aldh3b2       | 1.07        | 0.0065  | Aldehyde dehydrogenase 3 family, member B2 |
| Trim7         | -1.03       | 0.0079  | Tripartite motif-containing 7       |
| Nphp3         | -1.05       | 0.009   | Nephronphthisis 3 (adolescent)      |

https://doi.org/10.1371/journal.pone.0183854.t004
other exogenous insults [70]. There is strong evidence for abnormal expression levels of some cytokines in both the brain and peripheral blood of patients with schizophrenia, which have culminated in a cytokine-based model of the disease [41, 71]. Based on the behavioral and brain morphological changes we observed in the Slc1a1-HET mice, as well as the observations of over-represented immune pathways in the RNA sequencing data and altered brain redox status, we next sought to determine whether there was evidence of neuroinflammation in the brains of Slc1a1-HET mice by measurement of cytokine protein levels. Our results indicated a significantly increased production of proinflammatory cytokines, IL-4, IL-5, IL-13, IL-17A, IP-10/CXCL10, and RANTES/CCL5 in the brains of Slc1a1-HET mice, compared to WT mice (Table 7; Fig 7).

### Table 5. Functional enrichment of 74 differentially expressed genes (from Table 4) in blood tissue of Slc1a1-HET and WT mice.

| GO-Biological Process Pathways | Pathway ID | Pathway Description | Gene Count | FDR | Genes |
|-------------------------------|------------|---------------------|------------|-----|-------|
| GO.0043922                    | Negative regulation by host of viral transcription | 3          | 0.043 | Ccl3, Ccl4, Jun |
| GO.0002375                    | Immune system process | 14         | 0.047 | Ccl3, Ccl4, Clnk, Fasl, Ifng, Ifr7, Jun, Junb, Kit, Mylpf, Osm, Rhd, Tbx21, Trnk1 |
| GO.002763                     | Positive regulation of myeloid leukocyte differentiation | 4          | 0.047 | Ccl3, Fos, Ifng, Jun |
| GO.0006955                    | Immune response | 10         | 0.047 | Ccl3, Ccl4, Clnk, Fasl, Ifng, Ifr7, Kit, Mylpf, Osm, Trnk1 |
| GO.0050900                    | Leukocyte migration | 5          | 0.047 | Ccl3, Ccl4, Ifng, Kit, Tbx21 |
| GO.002891                     | Positive regulation of immunoglobulin mediated immune response | 3          | 0.048 | Fcer2a, Ifng, Tbx21 |
| GO.0006925                    | Inflammatory cell apoptotic process | 2          | 0.048 | Fasl, Ifng |
| GO.009314                     | Response to radiation | 7          | 0.048 | Cirbp, Dlt, Dusp1, Fos, Jun, Junb, Plk3 |
| GO.030595                    | Leukocyte chemotaxis | 4          | 0.048 | Ccl3, Ccl4, Ifng, Kit |
| GO.032496                     | Response to lipopolysaccharide | 6          | 0.048 | Ccl3, Fasl, Fos, Ifng, Jun, Junb |
| GO.034097                     | Response to cytokine | 8          | 0.048 | Darc, Fos, Ifng, Jun, Junb, Kit, Osm, Socs2 |
| GO.042493                     | Response to drug | 7          | 0.048 | Ccl3, Ccl4, Fos, Ifng, Jun, Junb, Prnp |
| GO.004572                     | Positive regulation of osteoclast differentiation | 3          | 0.048 | Ccl3, Fos, Ifng |
| GO.0051951                    | Response to cAMP | 4          | 0.048 | Dusp1, Fos, Jun, Junb |
| GO.070887                     | Cellular response to chemical stimulus | 14         | 0.048 | Ccl3, Darc, Dusp1, Fos, Ifng, Jun, Junb, Kit, Osm, Plk3, Ppp1r15a, Prnp, Slc16a1, Socs2, Tbx21 |
| GO.199441                     | Negative regulation of transcription from RNA polymerase II promoter in response to ER stress | 2          | 0.048 | Jun, Ppp1r15a |

| KEGG Pathways | Pathway ID | Pathway Description | Gene Count | FDR | Genes |
|---------------|------------|---------------------|------------|-----|-------|
| 5132          | Salmonella infection | 6          | 2.00E-05 | Ccl3, Ccl4, Fos, Ifng, Jun, Tjp1 |
| 4060          | Cytokine-cytokine receptor interaction | 7          | 0.001 | Ccl3, Ccl4, Fasl, Ifng, Kit, Osm, Trfnsf9 |
| 4629          | Toll-like receptor signaling pathway | 5          | 0.001 | Ccl3, Ccl4, Fos, Irf7, Jun |
| 5142          | Chagas disease (American trypanosomiasis) | 5          | 0.001 | Ccl3, Fasl, Fos, Ifng, Jun |
| 5323          | Rheumatoid arthritis | 4          | 0.004 | Ccl3, Fos, Ifng, Jun |
| 5168          | Herpes simplex infection | 5          | 0.009 | Fasl, Fos, Ifng, Irf7, Jun |
| 5144          | Malaria | 3          | 0.01 | Darc, Gypa, Ifng |
| 4380          | Osteoclast differentiation | 4          | 0.012 | Fos, Ifng, Jun, Junb |
| 5231          | Inflammatory bowel disease (IBD) | 3          | 0.017 | Ifng, Jun, Tbx21 |
| 5161          | Hepatitis B | 4          | 0.018 | Fasl, Fos, Irf7, Jun |
| 5140          | Leishmaniasis | 3          | 0.019 | Fos, Ifng, Jun |
| 5164          | Influenza A | 4          | 0.028 | Fasl, Ifng, Irf7, Jun |

https://doi.org/10.1371/journal.pone.0183854.t005
Table 6. Upstream regulator findings for differentially expressed genes in brain and blood.

### Brain

| Upstream Regulator | Molecule Type | Activation Z-Score | P-Value of Overlap | Target Molecules in Dataset |
|--------------------|---------------|--------------------|--------------------|----------------------------|
| TGFβ1              | Growth factor | 1.94               | 3.24E-02           | GRIN2A, JUNB, P4HA1,PPP1R3C,PRKCA,SLIT3,TNFAIP6 |
| Forskolin          | Chemical toxicant | 1.92            | 3.52E-02           | ARC, JUNB,PPP1R3C,TNFAIP6 |
| Lipopolysaccharide (LPS) | Chemical drug | 1.68             | 1.14E-02           | ARC, EFNB2,FOXG1,JUNB,P4HA1,PRKCA,SCUBE1,TNFAIP6 |
| APP                | Other         | 1.52               | 2.23E-02           | ARC, GRIN2A, JUNB, NR1D1, PRKCA |
| Morphine           | Chemical drug | 1.51               | 1.24E-04           | ARC, GRIN2A, JUNB, SLC1A1 |
| Tumor Necrosis Factor (TNF) | Cytokine | 1.4              | 8.44E-04           | ARC, EFNB2,JUNB,LAMA4,PPP1R3C,PRKCA, RGS14, SCUBE1, TNFAIP6, ZNF318 |
| Cocaine            | Chemical drug | 1.22               | 3.13E-04           | ARC, EFN2B, JUNB, Zfp948 |
| CREB1              | Transcription regulator | 1.07       | 1.90E-02           | ARC, JUNB, SORCS3, Zfp948 |
| LY294002           | Kinase inhibitor | 1.0           | 1.42E-02           | ADIPOR2, EFNB2, JUNB, SLC1A1 |
| FGF2               | Growth factor | 0.96               | 4.42E-03           | ARC, EFN2B, GRIN2A, JUNB |
| IL1B               | Cytokine      | 0.65               | 5.16E-03           | ARC, DBP, JUNB, NR1D1, SCUBE1, TNFAIP6 |
| Phorbol Myristate Acetate (PMA) | Chemical drug | 0.61             | 3.41E-03           | DBP, EFN2B, GRIN2A, JUNB, PRKCA, SLITRK3, TNFAIP6 |
| IFNG               | Cytokine      | 0.58               | 5.32E-04           | ARC, DBP, EFN2B, JUNB, NR1D1, PRKCA, SCUBE1, SLC6A6, TNFAIP6 |
| Ca2+               | Chemical—endogenous | 0.28         | 1.39E-03           | ARC, DBP, JUNB, NR1D1 |
| L-dopa             | Chemical—endogenous | 0.15         | 3.79E-02           | ARC, DBP, JUNB, RGS14 |
| NFkB (complex)     | Complex       | 0.0                | 2.63E-02           | DBP, JUNB, NR1D1, TNFAIP6 |
| Beta-estradiol     | Chemical—endogenous | -0.21      | 1.40E-03           | ARC, CHRM1, EFN2B, FOXG1, GRIN2A, JUNB, LMO7, PPP1R3C, Srsf5, TNFAIP6 |
| PKC(s)             | Group         | -0.53              | 6.42E-04           | DBP, JUNB, NR1D1, PRKCA |
| ESR1               | Ligand-dependent nuclear receptor | -1.63  | 9.79E-03           | AP1M1, EFN2B, JUNB, NR1D1, PPP1R3C, SLC6A6, TNFAIP6 |
| 2-amino-5-phosphonovaleric acid | Chemical | -1.96          | 1.51E-04           | ARC, DACT2, JUNB, SLITRK3 |

### Blood

| Upstream Regulator | Molecule Type | Activation Z-Score | P-Value of Overlap | Target Molecules in Dataset |
|--------------------|---------------|--------------------|--------------------|----------------------------|
| Lipopolysaccharide (LPS) | Chemical drug | 3.67             | 1.31E-09           | CCL3L3, CCL4, CENPI, DUSP1, Erdr1, FASLG, FOS, GAFAP, IFNG, IRF7, JUN, JUNB, KIT, OSM, PLK3, PPP1R15A, RGS1, SOCS2, TBX21, TNFRSF9 |
| Tumor Necrosis Factor (TNF) | Cytokine | 3.54             | 2.77E-13           | CCL3L3, CCL4, CTSF, DUSP1, FADSL, FASLG, FCER2, FOS, GAFAP, IFNG, IRF7, JUN, JUNB, KIT, OSM, PLK3, PPP1R15A, PRNP, RGS1, RRM2, SOCS2, TBX21, TJP1, TNFRSF9 |
| Phorbol Myristate Acetate (PMA) | Chemical drug | 3.38         | 4.50E-12           | CCL3L3, CCL4, DTL, DUSP1, FASLG, FOS, IFNG, IRF7, JUN, JUNB, KIT, MYLPF, OSM, PPP1R15A, PRNP, RGS1, SLC16A1, TBX21, TJP1 |
| Poly rI: rC-RNA | Biologic drug | 3.35             | 4.93E-10           | CCL3L3, CCL4, DUSP1, FASLG, FOS, IFNG, IRF7, JUN, JUNB, Oas1d, PPP1R15A, RGS1 |
| IL1B               | Cytokine      | 3.31               | 1.78E-10           | CCL4, CTSF, DUSP1, FASLG, FCER2, FOS, IFNG, IRF7, JUN, JUNB, OSM, PLK3, SOCS2, TBX21, TJP1, TNFRSF9 |
| IL2                | Cytokine      | 3.24               | 8.18E-10           | CCL3L3, CCL4, CDC6, FASLG, FOS, GAFAP, IFNG, JUN, KIT, OSM, SOCS2, TBX21, TJP1, TMOD1 |
| IFNG               | Cytokine      | 3.2                | 9.52E-10           | CCL3L3, CCL4, CIRBP, DUSP1, FASLG, FCER2, FOS, GAFAP, IFNG, IRF7, JUN, JUNB, OSM, PRNP, SOCS2, TBX21, TJP1, TMOD1 |

(Continued)
to the levels of β-tubulin, the observed differences cannot be attributed to different amounts of total protein in the lysates. We also found a significant effect of Sex on the concentrations of a subset of the above cytokines (IL-4, IL-5, IP-10 and RANTES), although it did not follow a consistent pattern among different cytokines (Table 7). Interestingly, we also found significant correlations between many of the cytokine levels in the samples (Table 8).

**SLC1A1 knockdown or overexpression affects neural cytokine release following oxidative or inflammatory challenge.** We next examined how overexpression or knockdown of SLC1A1 might affect the response of differentiated human neuroblastoma SK-N-SH cells to oxidative stress or pro-inflammatory stimuli using rotenone or LPS treatment. The choice of LPS was particularly appropriate given the evidence from the upstream regulator analysis of brain and blood in Slc1a1-HET mice that LPS could produce some of the same gene expression changes that were observed. Using real-time PCR, we first confirmed that in SK-N-SH cells treated with SLC1A1 shRNA or cDNA-containing plasmids, the expression level of this gene was significantly decreased (-1.53 fold, p = 0.039; Fig 8) or increased (+2.4 fold, p = 0.004; Fig 8), respectively.

Our results from cytokine profiling assay indicated that when SK-N-SH cells were exposed to the complex I inhibitor rotenone or the vehicle (DMSO), SLC1A1 expression level displayed an inverse relationship with released cytokine/chemokine levels. In other words, SLC1A1 knockdown increased and SLC1A1 overexpression decreased the release of several inflammatory cytokines or chemokines under baseline conditions or in response to rotenone, including Fractalkine, ITAC, TNFalpha, GM-CSF, MIP-3alpha, and interleukins 4, 6, 7, 8, 10, 17A and 21 (Fig 9). However, the expression level of SLC1A1 did not appear to have any consistent effects on cytokine production following the stimulation with LPS, suggesting that the anti-inflammatory functions of SLC1A1/EAAT3 might not be sufficient to overcome the effects of the potent inflammatory agent LPS. A two-way ANOVA (Construct x Treatment) of the data confirmed a significant effect of SLC1A1 construct (overexpression or knockdown) and cell

---

**Table 6. (Continued)**

| NFkB (complex) | Cytokine | 3.2 | 2.11E-09 | CCL3L3, CCL4, FASLG, FCER2, FOS, GFAP, IFNG, IRF7, JUN, JUNB, KIT, PLK3, TNFRSF9 |
|---------------|----------|-----|----------|---------------------------------------------------------------------------|
| CSF2          | Cytokine | 2.95| 9.21E-10 | CCL3L3, CCL4, FOS, IFNG, OSM, PPP1R15A, PRNP, RRM2, SG01, SKA1, SOCS2, TNFRSF9 |
| CD3           | Complex  | -2.87| 3.54E-06 | CCL3L3,CCL4,FASLG,FOS,IFNG,JUN,JUNB,SOCS2,TBX21, TNFRSF9                  |
| IKBKB         | Kinase    | 2.8 | 7.31E-10 | CCL3L3, CCL4, CDC6, CTSF, FASLG, FOS, IFNG, JUNB, SOCS2, TNFRSF9           |
| RELA          | Transcription regulator | 2.78 | 3.77E-07 | DUSP1, FASLG, FOS, IFNG, IRF7, JUN, JUNB, KIT, PLK3                       |
| P38 MAPK      | Group     | 2.76| 1.00E-09 | CCL3L3, DUSP1, FASLG, FCER2, FOS, IFNG, IRF7, JUN, JUNB, MYLPF, TXB21      |
| APP           | Other     | 2.76| 1.09E-06 | CCL3L3, CCL4, FASLG, FOS, GFAP, IFNG, IRF7, JUN, JUNB, OSM, PRNP, TPJ1     |
| TCR           | Complex   | 2.75| 3.06E-09 | CCL3L3, CCL4, FASLG, FOS, IFNG, IRF7, JUN, JUNB, SOCS2, TXB21              |
| IL1           | Group     | 2.71| 1.69E-06 | CCL4, DUSP1, FASLG, FOS, GFAP, IFNG, JUN, KIT                             |
| CD40          | Transmembrane receptor | 2.7 | 2.38E-09 | CCL4, DUSP1, FASLG, FCER2, FOS, IFNG, JUN, TXB21, TNFRSF9                |
| IL21          | Cytokine  | 2.62| 2.37E-07 | CCL3L3, CCL4, FASLG, IFNG, IRF7, SOCS2, TXB21                             |
| MAP2K1        | Kinase    | 2.62| 2.47E-07 | CCL3L3, CCL4, DUSP1, FASLG, FOS, JUN, OSM                                 |

Entries in bold are common between brain and blood.

https://doi.org/10.1371/journal.pone.0183854.t006
Fig 4. Predicted effects of upstream regulators on the levels of differentially expressed genes in brain and blood of Slc1a1−/− mice. IPA software was used to indicate the direction of change and relatedness of the common upstream regulators (n = 7) of the differentially expressed genes in the brain and blood of Slc1a1-HET mice. Genes that were changed in expression are shown in the perimeter of each diagram. Genes with significantly increased expression are colored in red and genes with significantly decreased expression are colored in green. The predicted upstream regulators are shown in the center. Orange dashed lines indicate predicted positive effects that are consistent with the observed changes in expression. Blue dashed lines indicate predicted negative effects that are consistent with the observed changes. Yellow dashed lines denote inconsistent predicted and observed effects.

https://doi.org/10.1371/journal.pone.0183854.g004
culture treatment (LPS, rotenone or vehicle) on all of the above cytokines, except IL-10, as well as a significant effect of their interaction on a subset of the cytokines studied (GM-CSF, MIP-3alpha, IL-4, IL-6, and IL-21; Table 9).

Discussion

In this report, we describe the first behavioral, anatomical, biochemical and transcriptional phenotypic analysis of late adolescent/young adult Slc1a1+/− mice. Our results lend considerable support to the potential utility of a mouse Slc1a1 haploinsufficiency model for mimicking the SLC1A1 hemi-deletion CNV we previously described in an extended Palauan family that co-segregated with schizophrenia and psychosis [43]. Our results are also highly consistent with the cellular phenotypic analysis we previously completed on the CNV [44].

The present study has the following major findings: 1) Slc1a1+/− mice appear to display several behavioral features that are consistent with well-established endophenotypes of schizophrenia and psychosis including anxiety-like behavior, impaired working memory, decreased exploratory activity and impaired sensorimotor gating. Moreover, these same effects appear to be present in KO Slc1a1−/− mice and are an equivalent magnitude; 2) Slc1a1+/− mice display reduced thickness of DMPFC, particularly layer V, which is also consistent with

![Graph showing decreased ratio of GSH/GSSG in Slc1a1-HET mice. The ratio of reduced to oxidized glutathione concentration (GSH/GSSG) in the brain tissue of Slc1a1-HET mice (n = 5) was found to be almost half of that in WT mice (n = 5). Data are shown as mean ± SEM. WT, wildtype; HET, heterozygous; GSH, reduced glutathione; GSSG, glutathione disulfide.](https://doi.org/10.1371/journal.pone.0183854.g005)
neuroanatomical findings in schizophrenia; 3) \textit{Slc1a1}^{+/}\mice exhibit a lower ratio of reduced to oxidized glutathione (GSH/GSSG) as well as a possible trend for increased oxidative DNA damage in the brain; 4) There appears to be compensatory or downstream effects in the brains of \textit{Slc1a1}^{+/}\mice, that lead to significant changes in the expression of genes and pathways involved in synaptic and cognitive functions; 5) There are robust changes in the expression of RNAs related to immune activation and inflammation in the blood of \textit{Slc1a1}^{+/}\mice; 6) The DMPFC of \textit{Slc1a1}^{+/}\mice shows evidence of increased production of inflammatory cytokines; and 7) \textit{SLC1A1} knockdown in human neuroblastoma cells increases, while \textit{SLC1A1} overexpression decreases, the release of several cytokines in response to an oxidative stress-inducing reagent. We now discuss some of the implications of these findings.

**Behavioral and brain morphological changes of \textit{Slc1a1}^{+/}\mice**

Most rodent models of schizophrenia have behavioral phenotype changes that resemble the positive-like symptoms of the disease, likely reflecting altered mesolimbic dopamine function. However, some models also show learning and memory impairment, analogous to cognitive symptoms of schizophrenia [72]. Using well-established behavioral paradigms that model...
aspects of schizophrenia [52], we found several phenotypes consistent with those seen in this disease in \textit{Slc1a1}^{+/−} mice.

**Increased anxiety-like behavior.** In the EPM test, \textit{Slc1a1}^{+/−} and \textit{Slc1a1}^{−/−} mice showed a non-significant tendency to enter closed arms more frequently and spend significantly longer time in those arms than WT mice. Although these differences were not significant, in the OF test, \textit{Slc1a1}^{+/−} and \textit{Slc1a1}^{−/−} mice also spent significantly less time in the anxiety-provoking center zone of the chamber compared to WT mice. The EPM test is one of the most popular tests for animal models of anxiety [52, 73]. It is believed that the aversion of mice to explore the open arms of the maze is caused by fear of open and elevated spaces, indicative of anxiety-like phenotype [74]. Similarly, the OF test assesses novel environment exploration and general locomotor activity, and provides a screen for anxiety-related behavior in mice. The results suggest that \textit{Slc1a1} deficiency might promote anxiety-like behavior in mice.

| Table 7. Results of cytokine profiling assay in \textit{Slc1a1}-HET vs. WT mouse brains. 
| --- | --- | --- | --- | --- | --- |
| **IL-4** | | | | | 
| Sex | Mean Square | F-Value | P-Value | Power | Scheffé’s post hoc test |
| --- | --- | --- | --- | --- | --- |
| Genotype | 6.88E-05 | 9.341 | 0.0109 | 0.804 | Mean Diff. Crit. Diff. P-Value |
| Sex * Genotype | 1.26E-04 | 17.129 | 0.0016 | 0.973 | F, M 0.00405 0.00309 0.0149 |
| **IL-13** | | | | | 
| Sex | 1.62E-07 | 0.73708 | 0.4089 | 0.11917 | Mean Diff. Crit. Diff. P-Value |
| Genotype | 4.72E-06 | 21.53244 | 0.0007 | 0.99249 | F, M 0.00011 0.00053 0.6724 |
| Sex * Genotype | 3.88E-07 | 1.76939 | 0.2104 | 0.21916 | HET, WT 0.00109 0.00053 0.0009 |
| **IL-5** | | | | | 
| Sex | 4.43E-06 | 10.99198 | 0.0069 | 0.86694 | Mean Diff. Crit. Diff. P-Value |
| Genotype | 0.00001 | 36.50142 | < 0.001 | 0.99994 | F, M 0.00093 0.00072 0.0165 |
| Sex * Genotype | 4.28E-07 | 1.06073 | 0.3252 | 0.15001 | HET, WT 0.00189 0.00072 0.0001 |
| **IL-17A** | | | | | 
| Sex | 1.00E-05 | 4.78509 | 0.0512 | 0.50654 | Mean Diff. Crit. Diff. P-Value |
| Genotype | 0.00001 | 9.44245 | 0.0106 | 0.80873 | F, M 0.00126 0.00137 0.0667 |
| Sex * Genotype | 8.58E-07 | 0.59603 | 0.4564 | 0.10589 | HET, WT 0.00186 0.00137 0.0123 |
| **IP-10/CXCL10** | | | | | 
| Sex | 2.00E-05 | 7.11 | 0.0219 | 0.68314 | Mean Diff. Crit. Diff. P-Value |
| Genotype | 0.00003 | 12.74488 | 0.0044 | 0.91371 | F, M 0.00191 0.00183 0.0417 |
| Sex * Genotype | 0.00001 | 2.80018 | 0.1224 | 0.32112 | HET, WT 0.00272 0.00183 0.0074 |
| **RANTES/CCL5** | | | | | 
| Sex | 1.55E-07 | 7.60029 | 0.0187 | 0.71373 | Mean Diff. Crit. Diff. P-Value |
| Genotype | 1.81E-07 | 8.87796 | 0.0125 | 0.78282 | F, M 0.00019 0.00016 0.0281 |
| Sex * Genotype | 3.78E-09 | 0.18528 | 0.6752 | 0.06753 | HET, WT 0.0002 0.00016 0.0183 |

Two way (Sex x Genotype) ANOVA, followed by Scheffé post hoc test. Only cytokines with significantly different concentrations that also survived FDR correction of the significant main effect of Genotype at q < 0.25 are displayed. Note that Scheffé post hoc tests confirmed the differences between Het and WT groups for all 6 of these cytokines.

https://doi.org/10.1371/journal.pone.0183854.t007
It is well known that anxiety disorders contribute to the etiology of psychiatric disorders, including schizophrenia [75]. Interestingly, SLC1A1 was the first positional candidate gene in the anxiety disorder obsessive compulsive disorder (OCD) [76, 77]. Among OCD positional candidate genes, SLC1A1 has among the strongest support for its association with this disorder [78–84]. Additionally, variations in SLC1A1 gene have also been associated with other forms of anxiety disorders, including posttraumatic stress disorder (PTSD) or anxiety symptom severity in autism spectrum disorder (ASD) [85, 86]. Thus, our observation of anxiety-like

Fig 7. Cytokines with different concentrations in Slc1a1-HET vs. WT mouse brains. Cytokine profiling assay was performed in the brains of a subset of the same Slc1a1-HET and WT mice used for behavioral phenotyping and morphometry (n = 4 males and 4 females per genotype, n = 16 total). To control for different amounts of total protein in the lysates, we normalized all of the cytokine concentrations to the levels of beta-tubulin in each sample. Comparisons between the groups were performed using a 2-way ANOVA (Sex x Genotype) with FDR correction of Genotype main effect p values and a Scheffé post-hoc test used to control for possible non-normality of the ratio data. Only those cytokines surviving FDR correction (q<0.25) are shown. WT, wildtype; HET, Slc1a1-heterozygous.

https://doi.org/10.1371/journal.pone.0183854.g007

Table 8. Correlation of differentially expressed cytokines in Slc1a1-HET and WT mouse brains.

|            | IL-4 | IL-13 | IL-5 | IL-17A | IP-10/CXCL10 | RANTES/CCL5 |
|------------|------|-------|------|--------|--------------|-------------|
| IL-4       |      | 0.0014| <.0001| <.0001 | <.0001       | <.0001      |
| IL-13      | 0.710|       | <.0001| <.0001 | <.0001       | <.0003      |
| IL-5       | 0.794| 0.799 |      |        | <.0001       | <.0001      |
| IL-17A     | 0.906| 0.796 | 0.739 |       | <.0001       | <.0001      |
| IP-10/CXCL10| 0.721| 0.816 | 0.844 | 0.793  |              | <.0001      |
| RANTES/CCL5| 0.831| 0.765 | 0.805 | 0.907  | 0.938        |             |

Pearson correlation coefficients (lower left half) and their statistical significance (top right half) between different cytokines in Slc1a1-HET and WT mouse brains. Bold coefficient values were statistically significant (p < 0.05).

https://doi.org/10.1371/journal.pone.0183854.t008
phenotype of Slc1a1+/− mice further supports the association of this gene with anxiety and its potential comorbidity with schizophrenia.

**Impaired working memory and reduced thickness of DMPFC.** Of the cognitive impairments in schizophrenia, substantial research has focused on working memory, typically defined as the ability, in the absence of sensory cues, to maintain and process information over short periods of time [87, 88]. The prefrontal cortex has been suggested as the primary site of working memory and subjects with schizophrenia, who are considered to have prefrontal cortical dysfunction, have demonstrated deficits on a variety of working memory tests [54]. Many parts of the brain, including hippocampus and basal forebrain, are thought to assist the prefrontal cortex in the performance of working memory tasks, particularly in rodents [89].

In our study, the Slc1a1+/− and Slc1a1−/− mice showed significantly impaired spontaneous alternation in the Y-maze test compared to WT mice. This paradigm is based on rodents’ innate tendency to explore novel environments and alternate between maze arms without any reinforcement and thereby, provides a measure of spatial working memory. Our gene expression data on the brains of Slc1a1+/− mice provides one possible explanation for these behavioral observations, based on the evidence for differential expression of genes related to synaptic function, cognitive function, and learning and memory in these mice.

![Fig 8. Confirmation of SLC1A1 expression changes in transfected differentiated SK-N-SH cells.](https://doi.org/10.1371/journal.pone.0183854.g008)
In humans, performance on working memory tasks depends, at least in part, upon the sustained firing of pyramidal cells in layers III and V of dorsolateral prefrontal cortex (DLPFC) [90]. There is evidence for aberrant activation of this brain region during working memory tasks in schizophrenic patients [88, 91]. Volumetric reductions of prefrontal cortex have also been reported in subjects with schizophrenia, which are correlated with the severity of cognitive and negative symptoms [61, 62]. Human postmortem studies have suggested that layers III and V of the DLPFC, which give rise to glutamatergic projections to neostriatum and pontine nuclei, demonstrate structural and transcriptome alterations in schizophrenia, including reports of a significant decrease in the thickness of cortical layer V in individuals with schizophrenia [92–95]. Interestingly, these layers overlap the localization of EAAT3-positive neurons in the forebrain, which are more numerous in projection layers III and V [7].

In support of this evidence, we found a significant 15% reduction in DMPFC overall thickness in Slc1a1<sup>−/−</sup> mice, but no change in overall brain mass or brain:body weight ratios. Although we detected the reduction in all cortical layers of the DMPFC of Slc1a1<sup>−/−</sup> mice, it

---

**Fig 9. SLC1A1 knockdown or overexpression affects the neural cytokine release following oxidative or inflammatory challenge.** The differentiated SK-N-SH cells subjected to overexpression or knockdown of SLC1A1 were treated with either LPS (100ng/mL) or rotenone (100nM) or 0.01% DMSO as the vehicle. Using a cytokine profiling assay, the levels of different cytokines in the supernatants of each transfection/treatment condition were measured. The cytokine results are displayed after hierarchical clustering. Two-way ANOVA indicated a significant effect of SLC1A1 expression level (shRNA or CDNA plasmid constructs) and treatment (LPS, RO or vehicle) on all but one cytokine (IL-10) and a significant effect of their interaction on several of the cytokines studied (GM-CSF, TNFalpha, MIP-3alpha, IL-4, IL-6, IL-21). Ctrl, control (non-target shRNA transfection); RO, rotenone; LPS, lipopolysaccharide.

https://doi.org/10.1371/journal.pone.0183854.g009
was most prominent in cortical layer V, the layer that contains large numbers of glutamatergic projection neurons. Many researchers have debated the homology between specific regions in primate and rodent forebrain. For example, the classically-defined DLPFC region of the primate brain does not exist in the rodent brain. However, it is believed that the rodent medial prefrontal cortex shares homology with the DLPFC region of the human brain [96, 97].

Overall, our results in the working memory task as well as in the morphometric and gene expression analyses support the association of Slc1a1 deficiency with cognitive impairments observed in schizophrenia. Our findings also lend support to the existing evidence in translational neuroscience regarding the cognitive tasks as behavioral outcome measures in animal models of psychosis and the potential involvement of rodents’ PFC circuitry in cognitive deficits seen in animal models of human diseases.

Decreased exploratory activity. In rodents, the NOR task, as measured by the amount of time taken to explore a new object in the presence of the familiar object, has become a benchmark task for assessing recognition memory. The hippocampus is involved in memory processing, recognition and storage of the contextual details and temporal order of previous experiences [98], and thus has been proposed as the main structure involved in object recognition memory in rodents [99]. We did not observe any gross morphological changes in cellular lamina or areal measures in the hippocampus of Slc1a1+/− mice, and we did not find any significant differences in performance of the NOR task in these mice. However, both Slc1a1+/− and Slc1a1−/− mice showed significantly diminished overall object exploratory activity as measured by total time spent in proximity to the objects. Although replicating negative symptoms of schizophrenia, such as anhedonia and avolition in animal models is difficult, reduced exploratory behavior is suggested as a measure of anhedonia in mice. In other words, it has been suggested that anhedonic mice display decreased duration of object exploration compared to control mice in the new object exploration paradigm [100]. Thus, we can speculate that decreased exploration of the objects in Slc1a1+/− mice might indicate their reduced interest in the objects, implying an anhedonic state in these animals. Alternatively, it is possible that the reduced interaction with the objects was related to reduced attention or to increased anxiety in Slc1a1+/− mice, which also spent less time in the center of the open field chamber.

Impaired sensory gating function. As the final behavioral phenotype examined, we found that in Slc1a1+/− and Slc1a1−/− mice, PPI of the acoustic startle reflex decreased to approximately half of that in WT mice. PPI is believed to reflect the sensorimotor gating process that occurs in the first few hundred milliseconds prior to conscious attention, filtering out weak
and unimportant stimuli and preventing sensory overload during a sensory task. Therefore, PPI is believed to reflect pre-attentive processing [58, 72]. Reduced PPI is commonly accepted as an endophenotype of schizophrenia, which models the positive symptoms of the disease across various species [59, 57, 101]. Our finding of a highly significant reduction in PPI (~48%) in Slc1a1+/− mice, suggests the importance of Slc1a1/EAAT3 in sensorimotor gating functions of the brain. Given our previous finding of the association of Slc1a1 disruptions with schizophrenia, this observation further supports the idea that PPI is likely to represent the “interface of psychosis and cognition” [57].

Biochemical imbalances in the brain of Slc1a1+/− mice

Altered glutathione redox state. EAAT3 is distinct from other EAATs in that besides transporting glutamate, it is also responsible for neuronal uptake of cysteine, the rate-limiting substrate for the synthesis of intracellular glutathione (GSH) [9, 102, 103]. GSH is the principal redox buffer in the CNS, protecting it against oxidative stress-induced cell damage and its deficiency is associated with neural cell death and neurodegenerative diseases [15, 104]. The significance of oxidative stress in the pathophysiology of schizophrenia is now well established [23, 105]. In fact, it has been proposed that different etiological factors of schizophrenia impose their effect by inducing cellular oxidative stress and damage [106]. Moreover, glutathione redox imbalances have been consistently reported in subjects with psychiatric disorders [65].

Given that a decreased ratio of reduced to oxidized glutathione concentration (GSH/GSSG) is an indicator of cellular toxicity and oxidative stress [64, 107], our finding of a significantly lower ratio of GSH/GSSG in Slc1a1+/− mice implicates a potential redox imbalance and higher vulnerability to oxidative stress in the brain as a result of Slc1a1 haploinsufficiency. Our results complement the previous reports of a decreased neuronal GSH content, increased oxidant levels and neurodegeneration in Slc1a1-null mice [11, 17, 19, 20] and indicates that even a partial loss of EAAT3 can make the cells vulnerable to oxidative stress. In addition, the expression of EAAT3 is known to increase following oxidative stress through the Nrf2-antioxidant responsive element (ARE) pathway [108]. When considered alongside these reports, our findings further implicate overexpression of EAAT3 as a bona fide neuroprotective mechanism to resist oxidative stress.

Increased oxidative DNA damage. One of the proposed mechanisms by which oxidative stress is involved in the pathology of schizophrenia is through oxidative DNA damage as a result of excessive ROS [109, 110]. The oxidative DNA damage might, in turn, stimulate cell cycle arrest and ultimately, cause cell death via apoptosis or necrosis [53]. In support of this idea, there is evidence for increased levels of 8-OHdG, a robust marker of oxidative DNA damage, in post-mortem hippocampus of patients with poor-prognosis schizophrenia [111]. In agreement with these reports, we found a trend for increased oxidative DNA damage in the brains of Slc1a1+/− mice.

No significant changes in the level of apoptosis markers. In contrast to the significant changes in redox status and possible elevation in DNA damage, we did not detect any changes in the level of apoptosis, as determined by active caspase-3 and phospho-BAD measurements in the brains of Slc1a1+/− mice. Such findings are consistent with our additional observation of no change in overall brain mass or brain:body weight ratios in Slc1a1+/− mice. The exact role of apoptosis in schizophrenia and the direction of its changes in the disease remain controversial [68]. On one hand, there have been reports of dysregulation of apoptosis and possible increase in apoptotic susceptibility in several brain regions of individuals with schizophrenia. On the other hand, accumulating evidence suggests that apoptotic activity may be downregulated in chronic schizophrenia [66–68]. In support of the latter hypothesis, the levels of active caspase-
3, which is the most important effector caspase involved in neuronal apoptosis, have been reported to be normal or even slightly decreased in the cortex of subjects with schizophrenia [112]. This observation is in contrast with what seen in neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases [68]. It is possible that downregulation of apoptotic activity in chronic schizophrenia could be influenced by antipsychotic medications, which have anti-inflammatory effects as well. In support of this hypothesis, studies have suggested that atypical antipsychotic pretreatment attenuated the rate of apoptosis in neural cells in vitro [113] and antipsychotic treatment in schizophrenia was associated with higher cortical levels of the anti-apoptotic marker Bcl-2, compared to antipsychotic-naïve subjects [114].

**Increased expression of inflammation-related genes and production of cytokines.** An emerging theory of schizophrenia derives from substantial evidence from neuroanatomical, environmental and genetic studies, which suggest that inflammation and immune dysfunction are involved in the pathogenesis of schizophrenia [41, 70, 71]. Cytokines and chemokines can play both pro- and anti-inflammatory roles and are among the most important components of the immune system, capable of penetrating the blood-brain barrier (BBB) to permit cross-talk between the CNS and immune system. However, when the balance of these inflammatory mediators is disrupted, they can induce neuronal inflammation, damage and degeneration, which can manifest in a variety of neuropsychiatric disorders [41, 71, 115].

In support of this idea, there is evidence that increased levels of inflammatory cytokines, following a genetic insult or exposure to oxidative stress or infectious agents, can contribute to cognitive, negative, and positive symptoms in schizophrenia [40]. Elevated levels of cytokines have been reported in postmortem brain and peripheral blood of subjects with schizophrenia [115, 116, 117]. Neuroimaging studies have shown active inflammation in the brains of patients with psychosis [118]. Conversely, subjects with psychosis exhibit reduced symptoms when administered anti-inflammatory agents [23, 119]. Furthermore, in genome-wide association studies, schizophrenia’s strongest association with genetic markers has been observed in the major histocompatibility complex (MHC) locus [120, 121]. The recent report of excessive complement C4 activity in the development of schizophrenia [42] adds to this body of evidence, which has collectively led to the emergence of a cytokine model for schizophrenia.

We found evidence for inflammation and immune dysfunction in Slc1a1−/− mice at both transcriptional and protein levels. At the protein level, our results suggested increased production of several inflammatory cytokines in the DMPFC of Slc1a1−/− mice. Two of the cytokines we profiled, IL-4 and IL-17A, were observed to change in the same direction in both Slc1a1−/− mice and following knockdown of SLC1A1 in SK-N-SH cells. In contrast, overexpression of SLC1A1 in SK-N-SH cells decreased the release level of these cytokines. Notably, the levels of these two cytokines in our samples were also highly correlated (R = 0.906). IL-4 is the key cytokine of the type 2 immune response and has been extensively studied in the context of its role in immunity. Accumulating evidence suggests that it plays a critical role in the regulation of cognitive functions of the brain, such as memory and learning [122]. Moreover, it has been suggested that cognitive task performance leads to the accumulation of IL-4–producing T cells in the meninges, and IL-4-null mice exhibit cognitive deficits [123].

Our whole transcriptome profiling studies of the brain and blood lend considerable support to the likelihood that there might be widespread immune activation or heightened inflammation in Slc1a1-deficient mice. Our data also point to several key molecules that might serve as master upstream regulators of these specific transcriptional responses in both the blood and brain. Manipulation of at least one of these predicted regulators—LPS—produced effects *in vitro* that were similar in nature to those seen in the mouse brain and blood. Although overexpression of SLC1A1 appeared highly effective at reducing the proinflammatory state produced by oxidative challenge with rotenone, we cannot claim that it was similarly effective at preventing
the striking inflammatory effect caused by LPS. Nonetheless, future research that examines the potential anti-inflammatory effects of SLC1A1 overexpression may prove fruitful under more physiological conditions in human subjects. Taken together, our findings support a potential anti-inflammatory function of SLC1A1/EAA3.

**Limitations and conclusions**

Our behavioral and biochemical results are largely based on a small number of mice studied during a single point in time, and should therefore be viewed as preliminary in nature, particularly the findings regarding morphometric outcomes. Nonetheless, they support the critical role of EAAT3 in neuronal glutathione synthesis and maintenance of the brain redox state and further support the role of glutathione and oxidative stress in the pathophysiology of schizophrenia. At least part of this role appears to involve oxidative damage of DNA and creation of a proinflammatory state in the brain and periphery.

**Acknowledgments**

We thank K. Gentile for technical assistance in performing the RNA-Seq studies.

**Author Contributions**

**Conceptualization:** Parisa Afshari, Wei-Dong Yao, Frank A. Middleton.

**Data curation:** Parisa Afshari, Frank A. Middleton.

**Formal analysis:** Parisa Afshari, Frank A. Middleton.

**Funding acquisition:** Wei-Dong Yao, Frank A. Middleton.

**Investigation:** Parisa Afshari, Frank A. Middleton.

**Methodology:** Parisa Afshari, Frank A. Middleton.

**Project administration:** Parisa Afshari, Frank A. Middleton.

**Resources:** Wei-Dong Yao, Frank A. Middleton.

**Supervision:** Frank A. Middleton.

**Validation:** Parisa Afshari, Frank A. Middleton.

**Visualization:** Parisa Afshari, Frank A. Middleton.

**Writing – original draft:** Parisa Afshari.

**Writing – review & editing:** Parisa Afshari, Frank A. Middleton.

**References**

1. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, et al. Localization of neuronal and glial glutamate transporters. Neuron. 1994; 13(3):713–725. PMID: 7917301
2. Danbolt NC. Glutamate transport. Prog Neurobiol. 2001; 65(1):1–105. PMID: 11369436
3. Kanai Y, Hediger MA. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature. 1992; 360(6403):467–471. https://doi.org/10.1038/360467a0 PMID: 1280334
4. Holmseth S, Dehnes Y, Huang YH, Follin-Arbelet VV, Grutle NJ, Mylonakou MN, et al. The density of EAAC1 (EAAT3) glutamate transporters expressed by neurons in the mammalian CNS. J Neurosci. 2012; 32(17):6000–6013. https://doi.org/10.1523/JNEUROSCI.3547-11.2012 PMID: 22539860
5. Diamond JS. Neuronal glutamate transporters limit activation of NMDA receptors by neurotransmitter spillover on CA1 pyramidal cells. J Neurosci. 2001; 21(21):8328–8338. PMID: 11606620
6. Scimemi A, Tian H, Diamond JS. Neuronal transporters regulate glutamate clearance, NMDA receptor activation, and synaptic plasticity in the hippocampus. J Neurosci. 2009; 29(46):14581–14595. https://doi.org/10.1523/JNEUROSCI.4845-09.2009 PMID: 19923291

7. Conti F, DeBiase S, Minelli A, Rothstein JD, Melone M. EAAC1, a high-affinity glutamate transporter, is localized to astrocytes and GABAergic neurons besides pyramidal cells in the rat cerebral cortex. Cereb Cortex. 1998; 8(2):108–116. PMID: 9542890

8. Sepkuty JP, Cohen AS, Eccles C, Rafiq A, Behar K, Ganel R, et al. A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy. J Neurosci. 2002; 22(15):6372–6379. PMID: 12151515

9. Zerangue N, Kavanaugh MP. Interaction of L-cysteine with a human excitatory amino acid transporter. J Physiol. 1996; 493(Pt 2):419–423.

10. Chen Y, Swanson RA. The glutamate transporters EAAT2 and EAAT3 mediate cysteine uptake in cortical neuron cultures. J Neurochem. 2003; 84(6):1332–1339. PMID: 12614333

11. Aoyama K, Nakaki T. Glutathione in Cellular Redox Homeostasis: Association with the Excitatory Amino Acid Carrier 1 (EAAC1). Molecules. 2015; 20(5):8742–8758. https://doi.org/10.3390/molecules20058742 PMID: 26007177

12. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol. 2000; 62(6):649–671. PMID: 10880854

13. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol. 2000; 62(6):649–671. PMID: 10880854

14. Bannai S, Kitamura E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J Biol Chem. 1980; 255(6):2372–2376. PMID: 7358676

15. Aoyama K, Watabe M, Nakaki T. Regulation of neuronal glutathione synthesis. J Pharmacol Sci. 2008; 108(3):227–238. PMID: 19008644

16. Lee S, Park SH, Zuo Z. Effects of isoflurane on learning and memory functions of wild-type and glutamate transporter type 3 knockout mice. J Pharm Pharmacol. 2012; 64(2):302–307. https://doi.org/10.1111/j.2042-7158.2011.01404.x PMID: 22221107

17. Cao L, Li L, Zuo Z. N-acetylcysteine reverses existing cognitive impairments and increased oxidative stress in glutamate transporter type 3 deficient mice. Neuroscience. 2012; 220:85–89. https://doi.org/10.1016/j.neuroscience.2012.06.044 PMID: 22732503

18. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kund RW, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996; 16(3):675–686. PMID: 8785064

19. Berman AE, Chan WY, Brennan AM, Reyes RC, Adler BL, Suh SW, et al. N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse. Ann Neurol. 2011; 69(3):509–520. https://doi.org/10.1002/ana.22162 PMID: 21446024

20. Li L, Zuo Z. Glutamate transporter type 3 knockout reduces brain tolerance to focal brain ischemia in mice. J Cereb Blood Flow Metab. 2011; 31(5):1283–1292. https://doi.org/10.1038/jcbfm.2010.222 PMID: 21139629

21. Lane MC, Jackson JG, Krizman EN, Rothstein JD, Porter BE, Robinson MB. Genetic deletion of the neuronal glutamate transporter, EAAC1, results in decreased neuronal death after pilocarpine-induced status epilepticus. Neurochem Int. 2014; 73:152–158. https://doi.org/10.1016/j.neuint.2013.11.013 PMID: 24334055

22. Won SJ, Yoo BH, Brennan AM, Shin BS, Kauppinen TM, Berman AE, et al. EAAC1 gene deletion alters zinc homeostasis and exacerbates neuronal injury after transient cerebral ischemia. J Neurosci. 2010; 30(46):15409–15418. https://doi.org/10.1523/JNEUROSCI.2084-10.2010 PMID: 21084597

23. Steullet P, Cabungcal JH, Monin A, Dwir D, O'Donnell P, Cuenod M, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? Schizophr Res. 2016; 176(1):41–51. https://doi.org/10.1016/j.schres.2014.06.021 PMID: 25000913

24. Peghini P, Janzen J, Stoffel W. Glutamate transporter EAAC1-deficient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. EMBO J. 1997; 16(13):3822–3832. https://doi.org/10.1093/emboj/16.13.3822 PMID: 9233792

25. Levenson J, Weeber E, Selcher JC, Katgegaya LS, Sweat JD, Esken A. Long-term potentiation and contextual fear conditioning increase neuronal glutamate uptake. Nat Neurosci. 2002; 5(2):155–161. https://doi.org/10.1038/nn791 PMID: 1178834

26. Aoyama K, Nakaki T. Neuroprotective properties of the excitatory amino acid carrier 1 (EAAC1). Amino Acids. 2013; 45(1):133–142. https://doi.org/10.1007/s00726-013-1481-5 PMID: 23462929
27. Aoyama K, Nakaki T. Impaired glutathione synthesis in neurodegeneration. Int J Mol Sci. 2013; 14(10):21021–21044. https://doi.org/10.3390/ijms141021021 PMID: 24145751

28. Lin CI, Orlov I, Ruggiero AM, Dykes-Hoberg M, Lee A, Jackson M, et al. Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP-18. Nature, 2001; 410(6824):84–88. https://doi.org/10.1038/35065084 PMID: 11240246

29. Watabe M, Aoyama K, Nakaki T. Regulation of glutathione synthesis via interaction between glutamate transport-associated protein 3–18 (GTRAP-18) and excitatory amino acid carrier-1 (EAAC1) at plasma membrane. Mol Pharmacol. 2007; 72(5):1103–1110. https://doi.org/10.1124/mol.107.039461 PMID: 17646425

30. Aoyama K, Nakaki T. Inhibition of GTRAP-18 may increase neuroprotective glutathione (GSH) synthesis. Int J Mol Sci. 2012; 13(9):12017–12035. https://doi.org/10.3390/ijms130912017 PMID: 23109897

31. Aoyama K, Wang F, Matsumura N, Kiyonari H, Shioi G, Tanaka K, et al. Increased neuronal glutathione and neuroprotection in GTRAP-18-deficient mice. Neurobiol Dis. 2012; 45(3):973–982. https://doi.org/10.1016/j.nbd.2011.12.016 PMID: 22210510

32. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999; 122 (Pt 4):593–624.

33. Antonova E, Sharma T, Morris R, Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res. 2004; 70(2–3):117–145. https://doi.org/10.1016/j.schres.2003.12.002 PMID: 15329292

34. Bonilha L, Molnar C, Horner MD, Anderson B, Forster L, George MS, et al. Neurocognitive deficits and prefrontal cortical atrophy in patients with schizophrenia. Schizophr Res. 2008; 101(1–3):142–151. https://doi.org/10.1016/j.schres.2007.11.023 PMID: 18164594

35. Ehrlich S, Brauns S, Yendiki A, Ho BC, Calhoun V, Schulz SC, et al. Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. Schizophr Bull. 2012; 38(5):1050–1062. https://doi.org/10.1093/schbul/sbr018 PMID: 21436318

36. Bogerts B, Ashtrial M, Degroef G, Alvin JM, Bilder RM, Lieberman JA. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res. 1990; 35(1):1–13. PMID: 2367608

37. Lawrie SM, Whalley H, Kestelman JN, Abukmeil SS, Byrne M, Hodges A, et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet. 1999; 353(9146):30–33. https://doi.org/10.1016/S0140-6736(98)06244-8 PMID: 10023948

38. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl). 2004; 174(1):151–162.

39. Ganzola R, Maziade M, Duchesne S. Hippocampus and amygdala volumes in children and young adults at high-risk of schizophrenia: research synthesis. Schizophr Res. 2014; 156(1):76–86. https://doi.org/10.1016/j.schres.2013.03.030 PMID: 24794883

40. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015; 2(3):258–270. https://doi.org/10.1016/S2215-0366(14)00122-9 PMID: 26359903

41. Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci. 2010; 64(3):217–270. https://doi.org/10.1111/j.1440-1819.2010.02094.x PMID: 20602722

42. Sekar A, Biasia AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016; 530(7589):177–183. https://doi.org/10.1038/nature16549 PMID: 26814963

43. Myles-Worsley M, Tiobech J, Browning SR, Korn J, Goodman S, Gentile K, et al. Detection at the SLCA1 glutamate transporter gene co-segregates with schizophrenia and bipolar schizoaffective disorder in a 5-generation family. Am J Med Genet B Neuropsychiatr Genet. 2013; 162B(2):87–95. https://doi.org/10.1002/ajmg.b.32125 PMID: 23341099

44. Afshari P, Myles-Worsley M, Cohen OS, Tiobech J, Faraoe SV, Byerley W, et al. Characterization of a novel mutation in SLCA1 associated with schizophrenia. Mol Neuropsychiatr. 2015; 1(3):125–144. https://doi.org/10.1159/000433599 PMID: 26380821

45. Stewart LR, Hall AL, Kang SH, Shaw CA, Beaudet AL. High frequency of known copy number abnormalities and maternal duplication 9q11-q13 in patients with combined schizophrenia and epilepsy. BMC Med Genet. 2011; 12: 154. https://doi.org/10.1186/1471-2350-12-154 PMID: 22118885

46. Horuchi Y, Iida S, Koga M, Ishiguro H, Iijima Y, Inada T, et al. Association of SNPs linked to increased expression of SLCA1 with schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 2012; 159B(1):30–37. https://doi.org/10.1002/ajmg.b.31249 PMID: 22095641
47. Priebe L, Degenhardt F, Strohmaier J, Breuer R, Herms S, Witt SH, et al. Copy Number Variants in German Patients with Schizophrenia. PLoS One, 2013; 8(7).

48. Costain G, Lionel AC, Fu F, Stavropoulos DJ, Gazzellone MJ, Marshall CR, et al. Adult neuropsychiatric expression and familial segregation of 2q13 duplications. Am J Med Genet B Neuropsychiatr Genet, 2014; 165B(4):337–344. https://doi.org/10.1002/ajmg.b.32236 PMID: 24807792

49. Costain G, Lionel AC, Merico D, Forsythe P, Russell K, Lowther C, et al. Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays. Hum Mol Genet, 2013; 22(22):4452–4501. https://doi.org/10.1093/hmg/ddt297 PMID: 23813976

50. Rees E, Walters JT, Chambert KD, O'Dushliae C, Szatkiewicz J, Richards AL, et al. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Hum Mol Genet, 2014; 23(6):1669–1676. https://doi.org/10.1093/hmg/ddt540 PMID: 24163246

51. Porton B, Greenberg BD, Askland K, Serra LM, Gesmonde J, Rudnick G, et al. Isoforms of the neuronal glutamate transporter gene, SLC1A1 /EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder. Transl Psychiatry, 2013; 3:e259. https://doi.org/10.1038/tp.2013.35 PMID: 23695234

52. Crawley JN. What's Wrong With My Mouse: Behavioral Phenotyping of Transgenic and Knockout Mice. Wiley-Liss. 2007; 2nd edition. 544 p.

53. Klein JA, Ackerman SL. Oxidative stress, cell cycle, and neurodegeneration. J Clin Invest. 2003; 111(6):785–793. https://doi.org/10.1172/JCI18182 PMID: 12639981

54. Perry W, Heaton RK, Potterat E, Roebuck T, Minassian A, Braff DL. Working memory in schizophrenia: transient "online" storage versus executive functioning. Schizophr Bull. 2001; 27(1):157–176. PMID: 11215544

55. Muller JE, Koen L, Soraya S, Emsley RA, Stein DJ. Anxiety disorders and schizophrenia. Curr Psychiatry Rep. 2004; 6(4):255–261. PMID: 15260940

56. Leff TA, Voineskos AN, Kennedy JL, Levine B, Daskalakis ZJ. Treating working memory deficits in schizophrenia: a review of the neurobiology. Biol Psychiatry. 2014; 75(5):361–370. https://doi.org/10.1016/j.biopsych.2013.07.026 PMID: 24011822

57. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull. 2010; 36(2):246–270. https://doi.org/10.1093/schbul/sbp132 PMID: 19900963

58. Porosolt RD, Moser PC, Castagné V. Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther. 2010; 333(3):632–638. https://doi.org/10.1124/jpet.110.166710 PMID: 20200119

59. Powell SB, Zhou X, Geyer MA. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res. 2009; 204(2):282–294. https://doi.org/10.1016/j.bbr.2009.04.021 PMID: 19397931

60. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry. 1990; 47(2):181–188. PMID: 2405807

61. Cannon TD, Thompson PM, van Erp TG, Toga AW, Poutanen VP, Huttunen M, et al. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc Natl Acad Sci U S A. 2002; 99(5):3228–3233. https://doi.org/10.1073/pnas.052023499 PMID: 11867725

62. Potkin SG, Turner JA, Brown GG, McCarthy G, Greve DN, Glover GH, et al. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr Bull. 2009; 35(1):19–31. https://doi.org/10.1093/schbul/sbn162 PMID: 19042912

63. Adriano F, Caltagirone C, Spalletta G. Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist. 2012; 18(2):180–200. https://doi.org/10.1177/1073858410395147 PMID: 21531988

64. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta. 2003; 333(1):19–39. PMID: 12809732

65. Gu F, Chauhan V, Chauhan A. Glutathione redox imbalance in brain disorders. Curr Opin Clin Nutr Metab Care. 2015; 18(1):89–95. https://doi.org/10.1097/MCO.0000000000000134 PMID: 25405315

66. Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 29(5):846–858. https://doi.org/10.1016/j.pnpbp.2005.03.010 PMID: 15908096

67. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res. 2006; 81(1):47–53. https://doi.org/10.1016/j.schres.2005.08.014 PMID: 16226876
68. Jarskog LF. Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations. Curr Opin Psychiatry. 2006; 19(3):307–312. https://doi.org/10.1097/01.yco.0000218603.25346.8f PMID: 16612218

69. Kiryu-Seo S, Gamo K, Tachibana T, Tanaka K, Kiyama H. Unique anti-apoptotic activity of EAAC1 in injured motor neurons. EMBO J. 2006; 25(14):3411–3421. https://doi.org/10.1038/sj.emboj.7601225 PMID: 16858406

70. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010; 167:261–280. https://doi.org/10.1176/appi.ajp.2009.09030361 PMID: 20123911

71. Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry. 2014; 75(4):292–299. https://doi.org/10.1016/j.biopsych.2013.12.002 PMID: 24439555

72. Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol. 2011; 164(4):1162–1194. https://doi.org/10.1111/j.1476-5381.2011.01386.x PMID: 21449915

73. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010; 167:261–280. https://doi.org/10.1176/appi.ajp.2009.09030361 PMID: 20123911

74. Rodgers RJ, Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev. 1997; 21(6):801–810. PMID: 9415905

75. Komada M, Takao K, Miyakawa T. Elevated plus maze for mice. J Vis Exp. 2008;(22).pii: 1088.

76. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009; 35(2):383–402. https://doi.org/10.1093/schbul/sbn135 PMID: 19011234

77. Buckely PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009; 35(2):383–402. https://doi.org/10.1093/schbul/sbn135 PMID: 19011234

78. Willour VL, Yao Shugart Y, Samuels J, Grados MA, Greenberg BD, Knowles JA, et al. Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Arch Gen Psychiatry. 2006; 63(7):778–785. https://doi.org/10.1001/archpsyc.63.7.778 PMID: 16818867

79. Leckman JF, Kim YS. A primary candidate gene for obsessive-compulsive disorder. Arch Gen Psychiatry. 2006; 63(7):717–720. https://doi.org/10.1001/archpsyc.63.7.717 PMID: 16818860

80. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry. 2006; 63(7):769–776. https://doi.org/10.1001/archpsyc.63.7.769 PMID: 16818866

81. Grados MA, Specht MW, Sung HM, Fortune D. Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach. Expert Opin Drug Discov. 2013; 8(12):1515–1527. https://doi.org/10.1517/17460441.2013.845553 PMID: 24147578

82. Zhang J, Sheerin C, Mandel H, Banducci AN, Myrick H, Acierno R, et al. Variation in SLC1A1 is related to combat-related posttraumatic stress disorder. J Anxiety Disord. 2014; 28(8):902–907. https://doi.org/10.1016/j.janxdis.2014.09.013 PMID: 25445080

83. Barch DM, Smith E. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia. Biol Psychiatry. 2008; 64(1):11–17. https://doi.org/10.1016/j.biopsych.2008.03.003 PMID: 18400207
88. Lewis DA. Cortical circuit dysfunction and cognitive deficits in schizophrenia—implications for preemptive interventions. Eur J Neurosci. 2012; 35(12):1871–1878. https://doi.org/10.1111/j.1460-9568.2012.08156.x PMID: 22708598

89. Yoon T, Okada J, Jung MW, Kim JJ. Prefrontal cortex and hippocampus subserve different components of working memory in rats. Learn Mem. 2008; 15(3):97–105. https://doi.org/10.1101/lm.850808 PMID: 18285468

90. Goldman-Rakic PS. Cellular basis of working memory. Neuron. 1995; 14:477–485. PMID: 7695894

91. Perry W, Heaton RK, Poteret E, Roebuck T, Minassian A, Braff DL. Working memory in schizophrenia: transient "online" storage versus executive functioning. Schizophr Bull. 2001; 27(1):157–176. PMID: 11215544

92. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry. 1998; 55:215–224. PMID: 9510215

93. Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholtzer J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res. 2002; 57(2–3):127–138. PMID: 12223243

94. Black JE, Kodish IM, Grossman AW, Klintsova AY, Orlovskaya D, Vostrikov V, et al. Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry. 2004; 161:742–744. https://doi.org/10.1176/appi.ajp.161.4.742 PMID: 15056523

95. Arion D, Corradi JP, Tang S, Datta D, Boothe F, He A, et al. Distinct transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. Mol Psychiatry. 2015; 20(11):1397–1405. https://doi.org/10.1038/mp.2014.171 PMID: 25560755

96. Uylings HB, Groenewegen HJ, Kolb B. Do rats have a prefrontal cortex? Behav Brain Res. 2003; 146(1–2):3–17. PMID: 14643455

97. Bicks LK, Koike H, Akbarian S, Morishita S. Prefrontal Cortex and Social Cognition in Mouse and Man. Front Psychol. 2015; 6:1805. https://doi.org/10.3389/fpsyg.2015.01805 PMID: 26635701

98. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process. 2012; 13(2):93–110. https://doi.org/10.1007/s10339-011-0430-z PMID: 22160349

99. Broadbent NJ, Gaskin S, Squire LR, Clark RE. Object recognition memory and the rodent hippocampus. Learn Mem. 2009; 17(1):5–11. https://doi.org/10.1101/lm.1650110 PMID: 20028732

100. Strekalova T, Spanagel R, Bartsch D, Henn FA, Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology. 2004; 29(11):2007–2017. https://doi.org/10.1038/sj.npp.1300532 PMID: 15266532

101. Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull. 2007; 33(1):21–32. https://doi.org/10.1093/schbul/sbl049 PMID: 17088422

102. Sagara JI, Miura K, Bannai S. Maintenance of neuronal glutathione by glial cells. J Neurochem. 1993; 61(5):1672–1676. PMID: 8228986

103. Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med. 1999; 27(9–10):922–935. PMID: 10569625

104. Cooper AJ, Kristal BS. Multiple roles of glutathione in the central nervous system. Biol Chem. 1997; 378(8):793–802. PMID: 9377474

105. Emiliani FE, Sedlak TW, Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry. 2014; 27(3):185–190. https://doi.org/10.1097/YCO.0000000000000054 PMID: 24613987

106. Bošković M, Vovk T, Kores Plesničar B, Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol. 2011; 9(2):301–312. https://doi.org/10.2174/15701591179596595 PMID: 22131939

107. Gilbert HF. Redox control of enzyme activities by thiol/disulfide exchange. Methods Enzymol. 1984; 107:330–351. PMID: 6239077

108. Escartín C, Won SJ, Malgorn C, Auregan G, Berman AE, Chen PC, et al. Nuclear factor erythroid 2-related factor 2 facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 3 expression. J Neurosci. 2011; 31(20):7392–7401. https://doi.org/10.1523/JNEUROSCI.6777-10.2011 PMID: 21593323

109. Jorgensen A, Broedbaek K, Fink-Jensen A, Knorr U, Greisen Soendergaard M, Henriksen T, et al. Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res. 2013; 209(3):417–423. https://doi.org/10.1016/j.pscychresns.2013.01.033 PMID: 23465294
110. Sertan Copoglu U, Virit O, Hanifi Kokacya M, Orkmez M, Bulbul F, Binnur Erbagci A, et al. Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients. Psychiatry Res. 2015; 229(1–2):200–205. https://doi.org/10.1016/j.psychres.2015.07.036 PMID: 26213375

111. Nishioka N, Arnold SE. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2004; 12(2):167–175. PMID: 15010346

112. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry. 2004; 161(1):109–115. https://doi.org/10.1176/appi.ajp.161.1.109 PMID: 14702258

113. Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci. 2003; 17(8):1563–1570. PMID: 12752374

114. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry. 2000; 48(7):641–650. PMID: 11032975

115. Smyth AM, Lawrie SM. The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci. 2013; 11(3):107–117. https://doi.org/10.9758/cpn.2013.11.3.107 PMID: 24465246

116. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014; 155(1–3):101–108. https://doi.org/10.1016/j.schres.2014.03.005 PMID: 24704219

117. Nielsen J, Røge R, Pristed SG, Viuff AG, Thørner LW, et al. Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia. Schizophr Bull. 2015; 41(3):764–771. https://doi.org/10.1093/schbul/sbu118 PMID: 25154621

118. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009; 50(11):1801–1807. https://doi.org/10.2967/jnumed.109.066647 PMID: 19837763

119. Bumb JM, Enning F, Leweke FM. Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert Opin Pharmacother. 2015; 16(7):1049–1067. https://doi.org/10.1517/14656566.2015.1032248 PMID: 25866122

120. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511:421–427. https://doi.org/10.1038/nature13595 PMID: 25056061

121. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009; 460(7256):744–747. https://doi.org/10.1038/nature08186 PMID: 19571808

122. Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remember. J Immunol. 2012; 189(9):4213–4219. https://doi.org/10.4049/jimmunol.1202246 PMID: 23087426

123. Derecki NC, Cardani AN, Yang CH, Quinnes KM, Criffield A, Lynch KR, et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med. 2010; 207(5):1067–1080. https://doi.org/10.1084/jem.20091419 PMID: 20439540